{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T03:34:36Z","timestamp":1785641676877,"version":"3.56.0"},"reference-count":287,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder characterized by a wide range of motor and non-motor symptoms that lead to substantial disability over time, particularly in advanced stages, with a significant impact on patients\u2019 quality of life (QoL). Given the chronic and currently incurable nature of the disease, symptom management and the preservation of health-related QoL (HRQoL) are central therapeutic priorities from a patient-centered perspective. In this context, there has been a growing emphasis on the use of patient-reported outcome measures (PROMs) to capture the subjective burden of disease and to better reflect the real-world benefits of therapeutic interventions beyond traditional clinical endpoints. In parallel, increasing attention has been paid to the consequences of PD on caregivers, whose HRQoL is often substantially affected, especially as the disease progresses and care demands intensify in advanced PD. This narrative review synthesizes current evidence on HRQoL in advanced PD, with particular focus on the contribution of motor symptoms, non-motor symptoms, and other disease-related factors to HRQoL impairment in patients and caregivers. Additionally, the available data on the impact of advanced therapies on HRQoL outcomes in patients are critically discussed, highlighting their role in comprehensive, patient-centered care.<\/jats:p>","DOI":"10.1007\/s00702-026-03142-y","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:17:05Z","timestamp":1774955825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A narrative review of clinical and non-clinical determinants of health-related quality of life in advanced Parkinson\u2019s disease"],"prefix":"10.1007","author":[{"given":"Jon","family":"Rodriguez-Antiguedad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Bojtos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"3142_CR1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z","volume":"14","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Karlsen K et al (1999) Mental symptoms in Parkinson\u2019s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14:866\u2013874","journal-title":"Int J Geriatr Psychiatry"},{"key":"3142_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/jnnp.2005.083113","volume":"78","author":"D Aarsland","year":"2007","unstructured":"Aarsland D, Bronnick K, Ehrt U et al (2007) Neuropsychiatric symptoms in patients with Parkinson\u2019s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78:36\u201342. https:\/\/doi.org\/10.1136\/jnnp.2005.083113","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3142_CR3","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1212\/wnl.58.suppl_1.s51","volume":"58","author":"CH Adler","year":"2002","unstructured":"Adler CH (2002) Relevance of motor complications in Parkinson\u2019s disease. Neurology 58:S51-56. https:\/\/doi.org\/10.1212\/wnl.58.suppl_1.s51","journal-title":"Neurology"},{"key":"3142_CR4","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"3142_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70245","author":"J Aldred","year":"2025","unstructured":"Aldred J, Bouchard M, Mart\u00ednez\u2010Castrillo JC et al (2025) Efficacy and safety of Foslevodopa\/Foscarbidopa monotherapy in patients with Parkinson\u2019s Disease. Movement Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70245","journal-title":"Movement Disord Clin Pract"},{"key":"3142_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/13607863.2011.569477","volume":"15","author":"E Andreadou","year":"2011","unstructured":"Andreadou E, Anagnostouli M, Vasdekis V et al (2011) The impact of comorbidity and other clinical and sociodemographic factors on health-related quality of life in Greek patients with Parkinson\u2019s disease. Aging Ment Health 15:913\u2013921. https:\/\/doi.org\/10.1080\/13607863.2011.569477","journal-title":"Aging Ment Health"},{"key":"3142_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000113714","volume":"5","author":"A Antonini","year":"2008","unstructured":"Antonini A, Mancini F, Canesi M et al (2008) Duodenal Levodopa infusion improves quality of life in advanced Parkinson\u2019s disease. Neurodegener Dis 5:244\u2013246. https:\/\/doi.org\/10.1159\/000113714","journal-title":"Neurodegener Dis"},{"key":"3142_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS et al (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"key":"3142_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00702-020-02175-1","volume":"127","author":"A Antonini","year":"2020","unstructured":"Antonini A, Abbruzzese G, Berardelli A et al (2020) The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson\u2019s disease patients. J Neural Transm 127:881\u2013891. https:\/\/doi.org\/10.1007\/s00702-020-02175-1","journal-title":"J Neural Transm"},{"key":"3142_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P et al (2022) Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs 36:1269\u20131283. https:\/\/doi.org\/10.1007\/s40263-022-00963-9","journal-title":"CNS Drugs"},{"key":"3142_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00856-1","author":"A Antonini","year":"2025","unstructured":"Antonini A, Bergmans B, Kern DS et al (2025) Foslevodopa\/Foscarbidopa in younger patients earlier within advanced Parkinson\u2019s disease: post hoc analysis of a randomized trial. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-025-00856-1","journal-title":"Neurol Ther"},{"key":"3142_CR13","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/mds.30020","volume":"39","author":"L Armengou\u2010Garcia","year":"2024","unstructured":"Armengou\u2010Garcia L, Sanchez\u2010Catasus CA, Aviles\u2010Olmos I et al (2024) Unilateral magnetic resonance\u2013guided focused ultrasound lesion of the subthalamic nucleus in Parkinson\u2019s disease: a prospective study. Mov Disord 39:2230\u20132241. https:\/\/doi.org\/10.1002\/mds.30020","journal-title":"Mov Disord"},{"key":"3142_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106065","volume":"123","author":"S Aslam","year":"2024","unstructured":"Aslam S, Manfredsson F, Stokes A, Shill H (2024) \u201cAdvanced\u201d Parkinson\u2019s disease: a review. Parkinsonism Relat Disord 123:106065. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106065","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jns.2016.11.080","volume":"372","author":"M Auffret","year":"2017","unstructured":"Auffret M, Le Jeune F, Maurus A et al (2017) Apomorphine pump in advanced Parkinson\u2019s disease: effects on motor and nonmotor symptoms with brain metabolism correlations. J Neurol Sci 372:279\u2013287. https:\/\/doi.org\/10.1016\/j.jns.2016.11.080","journal-title":"J Neurol Sci"},{"key":"3142_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/jnnp-2013-306907","volume":"85","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Kefalopoulou Z, Tripoliti E et al (2014) Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson\u2019s disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry 85:1419\u20131425. https:\/\/doi.org\/10.1136\/jnnp-2013-306907","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3142_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.parkreldis.2022.01.018","volume":"96","author":"M Bailey","year":"2022","unstructured":"Bailey M, Anderson S, Stebbins G et al (2022) Comparison of motor, non-motor, and quality of life phenotype in Black and White patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 96:18\u201321. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.01.018","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70317","author":"G Baille","year":"2025","unstructured":"Baille G, Patte\u2010Karsenti N, Salardaine Q et al (2025) Switching from Levodopa\/Carbidopa intestinal gel to continuous subcutaneous Foslevodopa\/Carbidopa infusion in advanced Parkinson\u2019s Disease: a case series. Movement Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70317","journal-title":"Movement Disord Clin Pract"},{"key":"3142_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/ane.12726","volume":"136","author":"Y Balash","year":"2017","unstructured":"Balash Y, Korczyn AD, Knaani J et al (2017) Quality-of-life perception by Parkinson\u2019s disease patients and caregivers. Acta Neurol Scand 136:151\u2013154. https:\/\/doi.org\/10.1111\/ane.12726","journal-title":"Acta Neurol Scand"},{"key":"3142_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ane.13095","volume":"140","author":"Y Balash","year":"2019","unstructured":"Balash Y, Korczyn AD, Migirov AA, Gurevich T (2019) Quality of life in Parkinson\u2019s disease: a gender-specific perspective. Acta Neurol Scand 140:17\u201322. https:\/\/doi.org\/10.1111\/ane.13095","journal-title":"Acta Neurol Scand"},{"key":"3142_CR21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord 24:1641\u20131649. https:\/\/doi.org\/10.1002\/mds.22643","journal-title":"Mov Disord"},{"key":"3142_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.parkreldis.2004.12.005","volume":"11","author":"M Behari","year":"2005","unstructured":"Behari M, Srivastava AK, Pandey RM (2005) Quality of life in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 11:221\u2013226. https:\/\/doi.org\/10.1016\/j.parkreldis.2004.12.005","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.nrleng.2014.10.016","volume":"31","author":"K Berganzo","year":"2016","unstructured":"Berganzo K, Tijero B, Gonz\u00e1lez-Eizaguirre A et al (2016) Motor and non-motor symptoms of Parkinson\u2019s disease and their impact on quality of life and on different clinical subgroups. Neurolog\u00eda (Engl Ed) 31:585\u2013591. https:\/\/doi.org\/10.1016\/j.nrleng.2014.10.016","journal-title":"Neurolog\u00eda (Engl Ed)"},{"key":"3142_CR24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s11136-024-03646-8","volume":"33","author":"R Bhanupriya","year":"2024","unstructured":"Bhanupriya R, Haridoss M, Lakshmi GS, Bagepally BS (2024) Health-related quality of life in Parkinson\u2019s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores. Qual Life Res 33:1781\u20131793. https:\/\/doi.org\/10.1007\/s11136-024-03646-8","journal-title":"Qual Life Res"},{"key":"3142_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/mdc3.13348","volume":"9","author":"S Bjerknes","year":"2022","unstructured":"Bjerknes S, Toft M, Brandt R et al (2022) Subthalamic nucleus stimulation in Parkinson\u2019s disease: 5-year extension study of a randomized trial. Movement Disord Clin Pract 9:48\u201359. https:\/\/doi.org\/10.1002\/mdc3.13348","journal-title":"Movement Disord Clin Pract"},{"key":"3142_CR26","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"key":"3142_CR27","doi-asserted-by":"publisher","unstructured":"Bock MA, Brown EG, Zhang L, Tanner C (2022) Association of motor and nonmotor symptoms with health-related quality of life in a large online cohort of people with Parkinson disease. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000200113","DOI":"10.1212\/WNL.0000000000200113"},{"key":"3142_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3098","volume":"74","author":"AE Bond","year":"2017","unstructured":"Bond AE, Shah BB, Huss DS et al (2017) Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol 74:1412. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3098","journal-title":"JAMA Neurol"},{"key":"3142_CR29","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1212\/WNL.0000000000012246","volume":"97","author":"F Bove","year":"2021","unstructured":"Bove F, Mulas D, Cavallieri F et al (2021) Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology 97:e254\u2013e262. https:\/\/doi.org\/10.1212\/WNL.0000000000012246","journal-title":"Neurology"},{"key":"3142_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep32267","volume":"6","author":"P Bugalho","year":"2016","unstructured":"Bugalho P, Lampreia T, Miguel R et al (2016) Non-motor symptoms in Portuguese Parkinson\u2019s disease patients: correlation and impact on quality of life and activities of daily living. Sci Rep 6:32267. https:\/\/doi.org\/10.1038\/srep32267","journal-title":"Sci Rep"},{"key":"3142_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mdc3.13262","volume":"8","author":"P Bugalho","year":"2021","unstructured":"Bugalho P, Ladeira F, Barbosa R et al (2021) Progression in Parkinson\u2019s disease: variation in motor and non\u2010motor symptoms severity and predictors of decline in cognition, motor function, disability, and health\u2010related quality of life as assessed by two different methods. Mov Disord Clin Pract 8:885\u2013895. https:\/\/doi.org\/10.1002\/mdc3.13262","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/mdc3.12819","volume":"6","author":"C B\u00fcttner","year":"2019","unstructured":"B\u00fcttner C, Maack M, Janitzky K, Witt K (2019) The evolution of quality of life after subthalamic stimulation for Parkinson\u2019s disease: a meta-analysis. Mov Disord Clin Pract 6:521\u2013530. https:\/\/doi.org\/10.1002\/mdc3.12819","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR33","unstructured":"Caap-Ahlgren M, Dehlin O (2026) Insomnia and depressive symptoms in patients with Parkinson\u2019s disease Relationship to health-related quality of life. an interview study of patients living at home"},{"key":"3142_CR34","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/mds.21408","volume":"22","author":"FJ Carod-Artal","year":"2007","unstructured":"Carod-Artal FJ, Vargas AP, Martinez-Martin P (2007) Determinants of quality of life in Brazilian patients with Parkinson\u2019s disease. Mov Disord 22:1408\u20131415. https:\/\/doi.org\/10.1002\/mds.21408","journal-title":"Mov Disord"},{"key":"3142_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.parkreldis.2007.06.011","volume":"14","author":"FJ Carod-Artal","year":"2008","unstructured":"Carod-Artal FJ, Ziomkowski S, Mour\u00e3o Mesquita H, Mart\u00ednez-Martin P (2008) Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 14:102\u2013108. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.06.011","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.parkreldis.2013.06.005","volume":"19","author":"FJ Carod-Artal","year":"2013","unstructured":"Carod-Artal FJ, Mesquita HM, Ziomkowski S, Martinez-Martin P (2013) Burden and health-related quality of life among caregivers of Brazilian Parkinson\u2019s disease patients. Parkinsonism Relat Disord 19:943\u2013948. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/wnl.51.5.1245","volume":"51","author":"JH Carter","year":"1998","unstructured":"Carter JH, Nutt JG (1998) Family caregiving: a neglected and hidden part of health care delivery. Neurology 51:1245\u20131246. https:\/\/doi.org\/10.1212\/wnl.51.5.1245","journal-title":"Neurology"},{"key":"3142_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mds.870130108","volume":"13","author":"JH Carter","year":"1998","unstructured":"Carter JH, Stewart BJ, Archbold PG et al (1998) Living with a person who has Parkinson\u2019s disease: the spouse\u2019s perspective by stage of disease. Mov Disord 13:20\u201328. https:\/\/doi.org\/10.1002\/mds.870130108","journal-title":"Mov Disord"},{"key":"3142_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03769-y","volume":"24","author":"I Cassidy","year":"2024","unstructured":"Cassidy I, Doody O, Richardson M, Meskell P (2024) Quality of life and living with Parkinson\u2019s disease: a qualitative exploration within an Irish context. BMC Neurol 24:275. https:\/\/doi.org\/10.1186\/s12883-024-03769-y","journal-title":"BMC Neurol"},{"key":"3142_CR40","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/ene.15436","volume":"29","author":"A Castrioto","year":"2022","unstructured":"Castrioto A, Deb\u00fb B, Cousin E et al (2022) Long\u2010term independence and quality of life after subthalamic stimulation in Parkinson disease. Euro J Neurol 29:2645\u20132653. https:\/\/doi.org\/10.1111\/ene.15436","journal-title":"Euro J Neurol"},{"key":"3142_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-0115-3","volume":"6","author":"S Cernera","year":"2020","unstructured":"Cernera S, Eisinger RS, Wong JK et al (2020) Long-term Parkinson\u2019s disease quality of life after staged DBS: STN vs GPi and first vs second lead. NPJ Parkinsons Dis 6:13. https:\/\/doi.org\/10.1038\/s41531-020-0115-3","journal-title":"NPJ Parkinsons Dis"},{"key":"3142_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jocn.2015.05.059","volume":"25","author":"FCF Chang","year":"2016","unstructured":"Chang FCF, Kwan V, Van Der Poorten D et al (2016) Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson\u2019s disease. J Clin Neurosci 25:41\u201345. https:\/\/doi.org\/10.1016\/j.jocn.2015.05.059","journal-title":"J Clin Neurosci"},{"key":"3142_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O et al (2005) Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord 20:224\u2013230. https:\/\/doi.org\/10.1002\/mds.20279","journal-title":"Mov Disord"},{"key":"3142_CR44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/mds.22868","volume":"25","author":"KR Chaudhuri","year":"2010","unstructured":"Chaudhuri KR, Prieto\u2010Jurcynska C, Naidu Y et al (2010) The nondeclaration of nonmotor symptoms of Parkinson\u2019s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:704\u2013709. https:\/\/doi.org\/10.1002\/mds.22868","journal-title":"Mov Disord"},{"key":"3142_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/mdc3.14018","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Facheris MF, Bergmans B et al (2024) Improved sleep correlates with improved quality of life and motor symptoms with Foslevodopa\/Foscarbidopa. Movement Disord Clin Pract 11:861\u2013866. https:\/\/doi.org\/10.1002\/mdc3.14018","journal-title":"Movement Disord Clin Pract"},{"key":"3142_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3257623","volume":"2020","author":"K Chen","year":"2020","unstructured":"Chen K, Tan Y, Lu Y et al (2020) Effect of exercise on quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinson\u2019s Dis 2020:1\u201310. https:\/\/doi.org\/10.1155\/2020\/3257623","journal-title":"Parkinson\u2019s Dis"},{"key":"3142_CR47","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/j.wneu.2022.12.049","volume":"171","author":"J-C Chen","year":"2023","unstructured":"Chen J-C, Lu M-K, Chen C-M, Tsai C-H (2023) Stepwise dual-target magnetic resonance-guided focused ultrasound in tremor-dominant Parkinson disease: a feasibility study. World Neurosurg 171:e464\u2013e470. https:\/\/doi.org\/10.1016\/j.wneu.2022.12.049","journal-title":"World Neurosurg"},{"key":"3142_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jocn.2017.08.002","volume":"45","author":"S-M Choi","year":"2017","unstructured":"Choi S-M, Kim BC, Jung H-J et al (2017) Impact of pain and pain subtypes on the quality of life of patients with Parkinson\u2019s disease. J Clin Neurosci 45:105\u2013109. https:\/\/doi.org\/10.1016\/j.jocn.2017.08.002","journal-title":"J Clin Neurosci"},{"key":"3142_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1353-8020(01)00044-X","volume":"8","author":"EA Chrischilles","year":"2002","unstructured":"Chrischilles EA, Rubenstein LM, Voelker MD et al (2002) Linking clinical variables to health-related quality of life in Parkinson\u2019s disease. Parkinsonism Relat Disord 8:199\u2013209. https:\/\/doi.org\/10.1016\/S1353-8020(01)00044-X","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR50","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/hex.13254","volume":"24","author":"K Churruca","year":"2021","unstructured":"Churruca K, Pomare C, Ellis LA et al (2021) Patient\u2010reported outcome measures (PROMs): a review of generic and condition\u2010specific measures and a discussion of trends and issues. Health Expect 24:1015\u20131024. https:\/\/doi.org\/10.1111\/hex.13254","journal-title":"Health Expect"},{"key":"3142_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/ijerph18010198","volume":"18","author":"P Crispino","year":"2020","unstructured":"Crispino P, Gino M, Barbagelata E et al (2020) Gender differences and quality of life in Parkinson\u2019s disease. IJERPH 18:198. https:\/\/doi.org\/10.3390\/ijerph18010198","journal-title":"IJERPH"},{"key":"3142_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1046\/j.1468-1331.2002.00484.x","volume":"9","author":"E Cubo","year":"2002","unstructured":"Cubo E, Rojo A, Ramos S et al (2002) The importance of educational and psychological factors in Parkinson\u2019s disease quality of life. Euro J Neurol 9:589\u2013593. https:\/\/doi.org\/10.1046\/j.1468-1331.2002.00484.x","journal-title":"Euro J Neurol"},{"key":"3142_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1586\/14737167.4.4.413","volume":"4","author":"RA Cummins","year":"2004","unstructured":"Cummins RA, Lau AL, Stokes M (2004) HRQOL and subjective well-being: noncomplementary forms of outcome measurement. Expert Rev Pharmacoecon Outcomes Res 4:413\u2013420. https:\/\/doi.org\/10.1586\/14737167.4.4.413","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3142_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.parkreldis.2017.08.003","volume":"43","author":"A D\u2019Iorio","year":"2017","unstructured":"D\u2019Iorio A, Vitale C, Piscopo F et al (2017) Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson\u2019s disease. Parkinsonism Relat Disord 43:114\u2013117. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.08.003","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/mds.27283","volume":"33","author":"HS Dafsari","year":"2018","unstructured":"Dafsari HS, Silverdale M, Strack M et al (2018) Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson\u2019s disease. Mov Disord 33:421\u2013430. https:\/\/doi.org\/10.1002\/mds.27283","journal-title":"Mov Disord"},{"key":"3142_CR56","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mds.27626","volume":"34","author":"HS Dafsari","year":"2019","unstructured":"Dafsari HS, Martinez-Martin P, Rizos A et al (2019) EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s disease. Mov Disord 34:353\u2013365. https:\/\/doi.org\/10.1002\/mds.27626","journal-title":"Mov Disord"},{"key":"3142_CR57","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1002\/mds.23907","volume":"26","author":"C Daniels","year":"2011","unstructured":"Daniels C, Krack P, Volkmann J et al (2011) Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson\u2019s disease predictable? Mov Disord 26:2516\u20132521. https:\/\/doi.org\/10.1002\/mds.23907","journal-title":"Mov Disord"},{"key":"3142_CR58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","volume":"21","author":"VC De Cock","year":"2022","unstructured":"De Cock VC, Dodet P, Leu-Semenescu S et al (2022) Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol 21:428\u2013437. https:\/\/doi.org\/10.1016\/S1474-4422(22)00085-0","journal-title":"Lancet Neurol"},{"key":"3142_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.758","volume":"7","author":"O De Fabregues","year":"2017","unstructured":"De Fabregues O, Dot J, Abu\u2010Suboh M et al (2017) Long\u2010term safety and effectiveness of levodopa\u2010carbidopa intestinal gel infusion. Brain Behav 7:e00758. https:\/\/doi.org\/10.1002\/brb3.758","journal-title":"Brain Behav"},{"key":"3142_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13348-x","volume":"272","author":"A De La Cuadra-Grande","year":"2025","unstructured":"De La Cuadra-Grande A, Rejas J, Casado M\u00c1 et al (2025) Quality of life measures in Parkinson\u2019s disease: a systematic literature review of patient-reported outcomes measures (PROMs) and their psychometric properties. J Neurol 272:598. https:\/\/doi.org\/10.1007\/s00415-025-13348-x","journal-title":"J Neurol"},{"key":"3142_CR61","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/mds.21567","volume":"22","author":"BL Den Oudsten","year":"2007","unstructured":"Den Oudsten BL, Van Heck GL, De Vries J (2007) Quality of life and related concepts in Parkinson\u2019s disease: a systematic review. Mov Disord 22:1528\u20131537. https:\/\/doi.org\/10.1002\/mds.21567","journal-title":"Mov Disord"},{"key":"3142_CR62","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/mdc3.70254","volume":"12","author":"C Desjardins","year":"2025","unstructured":"Desjardins C, Salardaine Q, Brandel J, Baille G (2025) Clinical impact of switching from subcutaneous apomorphine to Foslevodopa\/Foscarbidopa in advanced Parkinson\u2019s disease: a real-world observational study ( FOSAPO ). Mov Disord Clin Pract 12:2330\u20132336. https:\/\/doi.org\/10.1002\/mdc3.70254","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR63","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 355:896\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa060281","journal-title":"N Engl J Med"},{"key":"3142_CR64","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/jnnp.2005.065334","volume":"76","author":"A Diamond","year":"2005","unstructured":"Diamond A (2005) The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry 76:1188\u20131193. https:\/\/doi.org\/10.1136\/jnnp.2005.065334","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3142_CR65","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","volume":"263","author":"S Drapier","year":"2016","unstructured":"Drapier S, Eusebio A, Degos B et al (2016) Quality of life in Parkinson\u2019s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol 263:1111\u20131119. https:\/\/doi.org\/10.1007\/s00415-016-8106-3","journal-title":"J Neurol"},{"key":"3142_CR66","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/ane.13260","volume":"142","author":"C Ehlers","year":"2020","unstructured":"Ehlers C, Timpka J, Odin P, Honig H (2020) Levodopa infusion in Parkinson\u2019s disease: individual quality of life. Acta Neurol Scand 142:248\u2013254. https:\/\/doi.org\/10.1111\/ane.13260","journal-title":"Acta Neurol Scand"},{"key":"3142_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.parkreldis.2004.08.006","volume":"11","author":"T Erola","year":"2005","unstructured":"Erola T, Karinen P, Heikkinen E et al (2005) Bilateral subthalamic nucleus stimulation improves health-related quality of life in Parkinsonian patients. Parkinsonism Relat Disord 11:89\u201394. https:\/\/doi.org\/10.1016\/j.parkreldis.2004.08.006","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","volume":"23","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Stocchi F, Pahwa R et al (2024) Safety and efficacy of continuous subcutaneous levodopa\u2013carbidopa infusion (ND0612) for Parkinson\u2019s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23:465\u2013476. https:\/\/doi.org\/10.1016\/S1474-4422(24)00052-8","journal-title":"Lancet Neurol"},{"key":"3142_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L et al (2019) Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol 19:50. https:\/\/doi.org\/10.1186\/s12883-019-1276-8","journal-title":"BMC Neurol"},{"key":"3142_CR70","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s00415-023-11615-3","volume":"270","author":"A Fasano","year":"2023","unstructured":"Fasano A, Garc\u00eda-Ramos R, Gurevich T et al (2023) Levodopa\u2013carbidopa intestinal gel in advanced Parkinson\u2019s disease: long-term results from COSMOS. J Neurol 270:2765\u20132775. https:\/\/doi.org\/10.1007\/s00415-023-11615-3","journal-title":"J Neurol"},{"key":"3142_CR71","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa\u2010carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12\u2010month, open\u2010label results. Mov Disord 30:500\u2013509. https:\/\/doi.org\/10.1002\/mds.26123","journal-title":"Mov Disord"},{"key":"3142_CR72","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.27338","volume":"33","author":"HH Fernandez","year":"2018","unstructured":"Fernandez HH, Boyd JT, Fung VSC et al (2018) Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease. Mov Disord 33:928\u2013936. https:\/\/doi.org\/10.1002\/mds.27338","journal-title":"Mov Disord"},{"key":"3142_CR73","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mdc3.13338","volume":"8","author":"G Fern\u00e1ndez-Pajar\u00edn","year":"2021","unstructured":"Fern\u00e1ndez-Pajar\u00edn G, Sesar \u00c1, Ares B et al (2021) Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients. Movement Disord Clin Pract 8:1216\u20131224. https:\/\/doi.org\/10.1002\/mdc3.13338","journal-title":"Movement Disord Clin Pract"},{"key":"3142_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2021.100129","volume":"6","author":"G Fern\u00e1ndez-Pajar\u00edn","year":"2022","unstructured":"Fern\u00e1ndez-Pajar\u00edn G, Sesar \u00c1, Jim\u00e9nez Mart\u00edn I et al (2022) Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson\u2019s disease: a prospective study of 22 patients. Clin Parkinsonism Relat Disord 6:100129. https:\/\/doi.org\/10.1016\/j.prdoa.2021.100129","journal-title":"Clin Parkinsonism Relat Disord"},{"key":"3142_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0546-z","volume":"14","author":"R Ferrer-Cascales","year":"2016","unstructured":"Ferrer-Cascales R, Caba\u00f1ero-Mart\u00ednez MJ, S\u00e1nchez-SanSegundo M et al (2016) Spanish version of the Parkinson\u2019s disease questionnaire-carer (PDQ-Carer). Health Qual Life Outcomes 14:154. https:\/\/doi.org\/10.1186\/s12955-016-0546-z","journal-title":"Health Qual Life Outcomes"},{"key":"3142_CR76","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1212\/WNL.0000000000000943","volume":"83","author":"D Floden","year":"2014","unstructured":"Floden D, Cooper SE, Griffith SD, Machado AG (2014) Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation. Neurology 83:1627\u20131633. https:\/\/doi.org\/10.1212\/WNL.0000000000000943","journal-title":"Neurology"},{"key":"3142_CR77","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"KA Follett","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s Disease. N Engl J Med 362:2077\u20132091. https:\/\/doi.org\/10.1056\/NEJMoa0907083","journal-title":"N Engl J Med"},{"key":"3142_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/362908","volume":"2013","author":"T Foltynie","year":"2013","unstructured":"Foltynie T, Magee C, James C et al (2013) Impact of duodopa on quality of life in advanced Parkinson\u2019s Disease: a UK case series. Parkinsons Dis 2013:1\u20135. https:\/\/doi.org\/10.1155\/2013\/362908","journal-title":"Parkinsons Dis"},{"key":"3142_CR79","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.22121","volume":"23","author":"EB Forsaa","year":"2008","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2008) Predictors and course of health-related quality of life in Parkinson\u2019s disease. Mov Disord 23:1420\u20131427. https:\/\/doi.org\/10.1002\/mds.22121","journal-title":"Mov Disord"},{"key":"3142_CR80","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/mds.23394","volume":"25","author":"DA Gallagher","year":"2010","unstructured":"Gallagher DA, Lees AJ, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson\u2019s disease and are we missing them? Mov Disord 25:2493\u20132500. https:\/\/doi.org\/10.1002\/mds.23394","journal-title":"Mov Disord"},{"key":"3142_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2019.00076","volume":"6","author":"MN Gallay","year":"2020","unstructured":"Gallay MN, Moser D, Rossi F et al (2020) MRgFUS pallidothalamic tractotomy for chronic therapy-resistant Parkinson\u2019s Disease in 51 consecutive patients: single center experience. Front Surg 6:76. https:\/\/doi.org\/10.3389\/fsurg.2019.00076","journal-title":"Front Surg"},{"key":"3142_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.601153","volume":"12","author":"MN Gallay","year":"2021","unstructured":"Gallay MN, Moser D, Magara AE et al (2021) Bilateral MR-guided focused ultrasound pallidothalamic tractotomy for Parkinson\u2019s disease With 1-year follow-up. Front Neurol 12:601153. https:\/\/doi.org\/10.3389\/fneur.2021.601153","journal-title":"Front Neurol"},{"key":"3142_CR83","doi-asserted-by":"publisher","DOI":"10.31083\/RN33482","volume":"80","author":"N Garc\u00eda-Agua Soler","year":"2025","unstructured":"Garc\u00eda-Agua Soler N, Garc\u00eda Trujillo L, Garc\u00eda-Ruiz AJ (2025) Cost of quality of life in advanced Parkinson\u2019s Disease: efficient strategies for disease assessment. Rev Neurol 80:33482. https:\/\/doi.org\/10.31083\/RN33482","journal-title":"Rev Neurol"},{"key":"3142_CR84","doi-asserted-by":"publisher","first-page":"285","DOI":"10.30773\/pi.2019.02.20","volume":"16","author":"F Gen\u00e7","year":"2019","unstructured":"Gen\u00e7 F, Yuksel B, Tokuc FEU (2019) Caregiver burden and quality of life in early and late stages of idiopathic Parkinson\u2019s Disease. Psychiatry Investig 16:285\u2013291. https:\/\/doi.org\/10.30773\/pi.2019.02.20","journal-title":"Psychiatry Investig"},{"key":"3142_CR85","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4103\/aian.aian_210_23","volume":"26","author":"GYG Gencer","year":"2023","unstructured":"Gencer GYG, Erdem N\u015e, Ipek L et al (2023) Caregiver burden and quality of life of caregivers for patients with Parkinson\u2019s disease treated with deep brain stimulation. Ann Indian Acad Neurol 26:530\u2013536. https:\/\/doi.org\/10.4103\/aian.aian_210_23","journal-title":"Ann Indian Acad Neurol"},{"key":"3142_CR86","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/ene.14147","volume":"27","author":"VJ Geraedts","year":"2020","unstructured":"Geraedts VJ, Feleus S, Marinus J et al (2020) What predicts quality of life after subthalamic deep brain stimulation in Parkinson\u2019s disease? A systematic review. Eur J Neurol 27:419\u2013428. https:\/\/doi.org\/10.1111\/ene.14147","journal-title":"Eur J Neurol"},{"key":"3142_CR87","doi-asserted-by":"publisher","first-page":"P372","DOI":"10.1093\/geronb\/63.6.P372","volume":"63","author":"B Goldsworthy","year":"2008","unstructured":"Goldsworthy B, Knowles S (2008) Caregiving for Parkinson\u2019s disease patients: an exploration of a stress-appraisal model for quality of life and burden. J Gerontol B Psychol Sci Soc Sci 63:P372\u2013P376. https:\/\/doi.org\/10.1093\/geronb\/63.6.P372","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"3142_CR88","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00415-010-5786-y","volume":"258","author":"JC G\u00f3mez-Esteban","year":"2011","unstructured":"G\u00f3mez-Esteban JC, Tijero B, Somme J et al (2011) Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson\u2019s disease. J Neurol 258:494\u2013499. https:\/\/doi.org\/10.1007\/s00415-010-5786-y","journal-title":"J Neurol"},{"key":"3142_CR89","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/j.wneu.2019.01.132","volume":"125","author":"A Gorecka-Mazur","year":"2019","unstructured":"Gorecka-Mazur A, Furgala A, Krygowska-Wajs A et al (2019) Activities of daily living and their relationship to health-related quality of life in patients with Parkinson disease after subthalamic nucleus deep brain stimulation. World Neurosurg 125:e552\u2013e562. https:\/\/doi.org\/10.1016\/j.wneu.2019.01.132","journal-title":"World Neurosurg"},{"key":"3142_CR90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.14802\/jmd.23042","volume":"17","author":"M Grall-Bronnec","year":"2024","unstructured":"Grall-Bronnec M, Verholleman A, Victorri-Vigneau C et al (2024) Parkinson\u2019s Disease, impulsive-compulsive behaviors, and health-related quality of life. J Mov Disord 17:82\u201388. https:\/\/doi.org\/10.14802\/jmd.23042","journal-title":"J Mov Disord"},{"key":"3142_CR91","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/j.1532-5415.2007.01384.x","volume":"55","author":"T Greene","year":"2007","unstructured":"Greene T, Camicioli R (2007) Depressive symptoms and cognitive status affect health-related quality of life in older patients with Parkinson\u2019s disease. J Am Geriatr Soc 55:1888\u20131890. https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01384.x","journal-title":"J Am Geriatr Soc"},{"key":"3142_CR92","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/jnnp-2023-332272","volume":"95","author":"A Gronostay","year":"2024","unstructured":"Gronostay A, Jost ST, Silverdale M et al (2024) Stratifying quality of life outcome in subthalamic stimulation for Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 95:630\u2013638. https:\/\/doi.org\/10.1136\/jnnp-2023-332272","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3142_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232764","volume":"15","author":"MT Gruber","year":"2020","unstructured":"Gruber MT, Witte OW, Grosskreutz J, Prell T (2020) Association between malnutrition, clinical parameters and health-related quality of life in elderly hospitalized patients with Parkinson\u2019s disease: a cross-sectional study. PLoS ONE 15:e0232764. https:\/\/doi.org\/10.1371\/journal.pone.0232764","journal-title":"PLoS ONE"},{"key":"3142_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02958-w","volume":"30","author":"S Han","year":"2025","unstructured":"Han S, Chu M, Ren Y et al (2025) Global, regional, and national epidemiology of neurological disorders and subcategories: incidence and disability-adjusted life years, 1990\u20132021. Eur J Med Res 30:711. https:\/\/doi.org\/10.1186\/s40001-025-02958-w","journal-title":"Eur J Med Res"},{"key":"3142_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/640707","volume":"2012","author":"KK Hanna","year":"2012","unstructured":"Hanna KK, Cronin-Golomb A (2012) Impact of anxiety on quality of life in Parkinson\u2019s disease. Parkinsons Dis 2012:1\u20138. https:\/\/doi.org\/10.1155\/2012\/640707","journal-title":"Parkinsons Dis"},{"key":"3142_CR96","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ageing\/31.5.349","volume":"31","author":"S Happe","year":"2002","unstructured":"Happe S (2002) The association between caregiver burden and sleep disturbances in partners of patients with Parkinson\u2019s disease. Age Ageing 31:349\u2013354. https:\/\/doi.org\/10.1093\/ageing\/31.5.349","journal-title":"Age Ageing"},{"key":"3142_CR97","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1468-1331.2008.02103.x","volume":"15","author":"E Havlikova","year":"2008","unstructured":"Havlikova E, Rosenberger J, Nagyova I et al (2008) Impact of fatigue on quality of life in patients with Parkinson\u2019s disease. Euro J Neurol 15:475\u2013480. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02103.x","journal-title":"Euro J Neurol"},{"key":"3142_CR98","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20","author":"MC Hechtner","year":"2014","unstructured":"Hechtner MC, Vogt T, Z\u00f6llner Y et al (2014) Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 20:969\u2013974. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR99","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/rep0000313","volume":"65","author":"RS Henry","year":"2020","unstructured":"Henry RS, Lageman SK, Perrin PB (2020) The relationship between Parkinson\u2019s disease symptoms and caregiver quality of life. Rehabil Psychol 65:137\u2013144. https:\/\/doi.org\/10.1037\/rep0000313","journal-title":"Rehabil Psychol"},{"key":"3142_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1034\/j.1600-0404.2003.02033.x","volume":"107","author":"K Herlofson","year":"2003","unstructured":"Herlofson K, Larsen JP (2003) The influence of fatigue on health-related quality of life in patients with Parkinson\u2019s disease: fatigue and health-related quality of life in PD. Acta Neurol Scand 107:1\u20136. https:\/\/doi.org\/10.1034\/j.1600-0404.2003.02033.x","journal-title":"Acta Neurol Scand"},{"key":"3142_CR101","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/mds.23961","volume":"27","author":"C Hinnell","year":"2012","unstructured":"Hinnell C, Hurt CS, Landau S et al (2012) Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson\u2019s disease? Mov Disord 27:236\u2013241. https:\/\/doi.org\/10.1002\/mds.23961","journal-title":"Mov Disord"},{"key":"3142_CR102","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/ageing\/28.4.341","volume":"28","author":"P Hobson","year":"1999","unstructured":"Hobson P (1999) Measuring the impact of Parkinson\u2019s disease with the Parkinson\u2019s Disease Quality of Life questionnaire. Age Ageing 28:341\u2013346. https:\/\/doi.org\/10.1093\/ageing\/28.4.341","journal-title":"Age Ageing"},{"key":"3142_CR103","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez\u2010Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468\u20131474. https:\/\/doi.org\/10.1002\/mds.22596","journal-title":"Mov Disord"},{"key":"3142_CR104","doi-asserted-by":"publisher","first-page":"63","DOI":"10.26719\/emhj.23.013","volume":"29","author":"Z Hoseinipalangi","year":"2023","unstructured":"Hoseinipalangi Z, Kan FP, Hosseinifard H et al (2023) Systematic review and meta-analysis of the quality-of-life of patients with Parkinson\u2019s disease. East Mediterr Health J 29:63\u201370. https:\/\/doi.org\/10.26719\/emhj.23.013","journal-title":"East Mediterr Health J"},{"key":"3142_CR105","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jns.2018.10.010","volume":"395","author":"J-F Houvenaghel","year":"2018","unstructured":"Houvenaghel J-F, Drapier S, Duprez J et al (2018) Effects of continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life. J Neurol Sci 395:113\u2013118. https:\/\/doi.org\/10.1016\/j.jns.2018.10.010","journal-title":"J Neurol Sci"},{"key":"3142_CR106","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/mds.30281","volume":"40","author":"J Ikezawa","year":"2025","unstructured":"Ikezawa J, Yokochi F, Yamaguchi T et al (2025) Bilateral effects of unilateral pallidothalamic tractotomy using focused ultrasound in Parkinson\u2019s Disease. Mov Disord 40:1983\u20131989. https:\/\/doi.org\/10.1002\/mds.30281","journal-title":"Mov Disord"},{"key":"3142_CR107","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1877718X241310727","volume":"15","author":"SH Isaacson","year":"2025","unstructured":"Isaacson SH, Espay AJ, Pahwa R et al (2025) Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: results from the phase 3, long-term, open-label United States InfusON study. J Parkinsons Dis 15:361\u2013373. https:\/\/doi.org\/10.1177\/1877718X241310727","journal-title":"J Parkinsons Dis"},{"key":"3142_CR108","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.parkreldis.2012.01.007","volume":"18","author":"C Jenkinson","year":"2012","unstructured":"Jenkinson C, Dummett S, Kelly L et al (2012) The development and validation of a quality of life measure for the carers of people with Parkinson\u2019s disease (the PDQ-Carer). Parkinsonism Relat Disord 18:483\u2013487. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.01.007","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR109","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52177","volume":"7","author":"ST Jost","year":"2024","unstructured":"Jost ST, Aloui S, Evans J et al (2024) Neurostimulation for advanced Parkinson disease and quality of life at 5 years: a nonrandomized controlled trial. JAMA Netw Open 7:e2352177. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52177","journal-title":"JAMA Netw Open"},{"key":"3142_CR110","doi-asserted-by":"publisher","unstructured":"Jung NY, Park CK, Kim M, et al (2018) The efficacy and limits of magnetic resonance\u2013guided focused ultrasound pallidotomy for Parkinson\u2019s disease: a Phase I clinical trial. J Neurosurg. https:\/\/doi.org\/10.3171\/2018.2.JNS172514","DOI":"10.3171\/2018.2.JNS172514"},{"key":"3142_CR111","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/mds.10111","volume":"17","author":"H Just","year":"2002","unstructured":"Just H, Ostergaard K (2002) Health-related quality of life in patients with advanced Parkinson\u2019s disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord 17:539\u2013545. https:\/\/doi.org\/10.1002\/mds.10111","journal-title":"Mov Disord"},{"key":"3142_CR112","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.neurom.2023.03.007","volume":"27","author":"J K\u00e4hk\u00f6l\u00e4","year":"2024","unstructured":"K\u00e4hk\u00f6l\u00e4 J, Katisko J, Lahtinen M (2024) Deep brain stimulation of Subthalamic Nucleus improves quality of life in general and mental health domains in Parkinson\u2019s Disease to the level of the general population. Neuromodulation 27:520\u2013527. https:\/\/doi.org\/10.1016\/j.neurom.2023.03.007","journal-title":"Neuromodulation"},{"key":"3142_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1149615","volume":"14","author":"A Kakimoto","year":"2023","unstructured":"Kakimoto A, Kawazoe M, Kurihara K et al (2023) Impact of non-motor fluctuations on QOL in patients with Parkinson\u2019s disease. Front Neurol 14:1149615. https:\/\/doi.org\/10.3389\/fneur.2023.1149615","journal-title":"Front Neurol"},{"key":"3142_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238329","volume":"14","author":"EA Katunina","year":"2025","unstructured":"Katunina EA, Martynov MY, Belousov VV et al (2025) The results of a 12-month open-label follow-up study with MRI monitoring of patients with Parkinson\u2019s disease after MRI-guided FUS. JCM 14:8329. https:\/\/doi.org\/10.3390\/jcm14238329","journal-title":"JCM"},{"key":"3142_CR115","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759. https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"key":"3142_CR116","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","volume":"83","author":"R Katzenschlager","year":"2021","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2021) Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord 83:79\u201385. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.024","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-57","volume":"12","author":"DH Kelly","year":"2012","unstructured":"Kelly DH, McGinley JL, Huxham FE et al (2012) Health-related quality of life and strain in caregivers of Australians with Parkinson\u2019s disease: an observational study. BMC Neurol 12:57. https:\/\/doi.org\/10.1186\/1471-2377-12-57","journal-title":"BMC Neurol"},{"key":"3142_CR118","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/mds.27783","volume":"34","author":"MJ Kelly","year":"2019","unstructured":"Kelly MJ, Lawton MA, Baig F et al (2019) Predictors of motor complications in early Parkinson\u2019s disease: a prospective cohort study. Mov Disord 34:1174\u20131183. https:\/\/doi.org\/10.1002\/mds.27783","journal-title":"Mov Disord"},{"key":"3142_CR119","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/imj.13378","volume":"47","author":"TE Kimber","year":"2017","unstructured":"Kimber TE, Fang J, Huddy LJ, Thompson PD (2017) Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J 47:570\u2013573. https:\/\/doi.org\/10.1111\/imj.13378","journal-title":"Intern Med J"},{"key":"3142_CR120","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1468-1331.2006.01604.x","volume":"14","author":"N Klepac","year":"2007","unstructured":"Klepac N, Pikija S, Kralji\u0107 T et al (2007) Association of rural life setting and poorer quality of life in Parkinson\u2019s disease patients: a cross\u2010sectional study in Croatia. Eur J Neurol 14:194\u2013198. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01604.x","journal-title":"Eur J Neurol"},{"key":"3142_CR121","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1468-1331.2007.02011.x","volume":"15","author":"N Klepac","year":"2008","unstructured":"Klepac N, Trkulja V, Relja M, Babi\u0107 T (2008) Is quality of life in non-demented Parkinson\u2019s disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol 15:128\u2013133. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.02011.x","journal-title":"Eur J Neurol"},{"key":"3142_CR122","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fneur.2018.00120","volume":"9","author":"M Klietz","year":"2018","unstructured":"Klietz M, Tulke A, M\u00fcschen LH et al (2018) Impaired quality of life and need for palliative care in a german cohort of advanced Parkinson\u2019s disease patients. Front Neurol 9:120. https:\/\/doi.org\/10.3389\/fneur.2018.00120","journal-title":"Front Neurol"},{"key":"3142_CR123","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3233\/JPD-212979","volume":"12","author":"N Kov\u00e1cs","year":"2022","unstructured":"Kov\u00e1cs N, Bergmann L, Anca-Herschkovitsch M et al (2022) Outcomes impacting quality of life in advanced Parkinson\u2019s disease patients treated with Levodopa-Carbidopa intestinal gel. J Parkinsons Dis 12:917\u2013926. https:\/\/doi.org\/10.3233\/JPD-212979","journal-title":"J Parkinsons Dis"},{"key":"3142_CR124","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/mds.27860","volume":"34","author":"P Krack","year":"2019","unstructured":"Krack P, Volkmann J, Tinkhauser G, Deuschl G (2019) Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord 34:1795\u20131810. https:\/\/doi.org\/10.1002\/mds.27860","journal-title":"Mov Disord"},{"key":"3142_CR125","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2202721","volume":"388","author":"V Krishna","year":"2023","unstructured":"Krishna V, Fishman PS, Eisenberg HM et al (2023) Trial of globus pallidus focused ultrasound ablation in Parkinson\u2019s disease. N Engl J Med 388:683\u2013693. https:\/\/doi.org\/10.1056\/NEJMoa2202721","journal-title":"N Engl J Med"},{"key":"3142_CR126","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12325-017-0571-2","volume":"34","author":"R Kr\u00fcger","year":"2017","unstructured":"Kr\u00fcger R, Lingor P, Doskas T et al (2017) An observational study of the effect of Levodopa\u2013Carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson\u2019s disease patients. Adv Ther 34:1741\u20131752. https:\/\/doi.org\/10.1007\/s12325-017-0571-2","journal-title":"Adv Ther"},{"key":"3142_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117172","volume":"419","author":"K Kurihara","year":"2020","unstructured":"Kurihara K, Nakagawa R, Ishido M et al (2020) Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: The Japanese Quality-of-Life Survey of Parkinson Disease (JAQPAD) study. J Neurol Sci 419:117172. https:\/\/doi.org\/10.1016\/j.jns.2020.117172","journal-title":"J Neurol Sci"},{"key":"3142_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00223-5","volume":"7","author":"ML Lachenmayer","year":"2021","unstructured":"Lachenmayer ML, M\u00fcrset M, Antih N et al (2021) Subthalamic and pallidal deep brain stimulation for Parkinson\u2019s disease\u2014meta-analysis of outcomes. NPJ Parkinsons Dis 7:77. https:\/\/doi.org\/10.1038\/s41531-021-00223-5","journal-title":"NPJ Parkinsons Dis"},{"key":"3142_CR129","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/01.wnl.0000037486.82390.1c","volume":"59","author":"E Lagrange","year":"2002","unstructured":"Lagrange E, Krack P, Moro E et al (2002) Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 59:1976\u20131978. https:\/\/doi.org\/10.1212\/01.wnl.0000037486.82390.1c","journal-title":"Neurology"},{"key":"3142_CR130","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.04.009","volume":"27","author":"RA Lawson","year":"2016","unstructured":"Lawson RA, Yarnall AJ, Duncan GW et al (2016) Cognitive decline and quality of life in incident Parkinson\u2019s disease: the role of attention. Parkinsonism Relat Disord 27:47\u201353. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.009","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107073","volume":"126","author":"C Ledda","year":"2024","unstructured":"Ledda C, Imbalzano G, Tangari MM et al (2024) NoMoFa as a new tool to evaluate the impact of deep brain stimulation on non-motor fluctuations: a new perspective. Parkinsonism Relat Disord 126:107073. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107073","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR132","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13390-9","volume":"272","author":"C Ledda","year":"2025","unstructured":"Ledda C, Imbalzano G, Scaglia E et al (2025) Nonmotor fluctuations in Parkinson\u2019s disease: impact on caregiving and quality of life. J Neurol 272:639. https:\/\/doi.org\/10.1007\/s00415-025-13390-9","journal-title":"J Neurol"},{"key":"3142_CR133","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/rnj.0000000000000158","volume":"44","author":"J Lee","year":"2019","unstructured":"Lee J, Kim SH, Kim Y et al (2019) Quality of life of caregivers of individuals with Parkinson\u2019s disease. Rehabil Nurs 44:338\u2013348. https:\/\/doi.org\/10.1097\/rnj.0000000000000158","journal-title":"Rehabil Nurs"},{"key":"3142_CR134","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/ageing\/afr078","volume":"40","author":"I Leroi","year":"2011","unstructured":"Leroi I, Ahearn DJ, Andrews M et al (2011) Behavioural disorders, disability and quality of life in Parkinson\u2019s disease. Age Ageing 40:614\u2013621. https:\/\/doi.org\/10.1093\/ageing\/afr078","journal-title":"Age Ageing"},{"key":"3142_CR135","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/0891988712464823","volume":"25","author":"I Leroi","year":"2012","unstructured":"Leroi I, McDonald K, Pantula H, Harbishettar V (2012) Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 25:208\u2013214. https:\/\/doi.org\/10.1177\/0891988712464823","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"3142_CR136","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00415-016-8077-4","volume":"263","author":"E Lezcano","year":"2016","unstructured":"Lezcano E, G\u00f3mez-Esteban JC, Tijero B et al (2016) Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson\u2019s disease. J Neurol 263:895\u2013905. https:\/\/doi.org\/10.1007\/s00415-016-8077-4","journal-title":"J Neurol"},{"key":"3142_CR137","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/mds.23368","volume":"25","author":"H Li","year":"2010","unstructured":"Li H, Zhang M, Chen L et al (2010) Nonmotor symptoms are independently associated with impaired health\u2010related quality of life in Chinese patients with Parkinson\u2019s disease. Mov Disord 25:2740\u20132746. https:\/\/doi.org\/10.1002\/mds.23368","journal-title":"Mov Disord"},{"key":"3142_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1449973","volume":"16","author":"M Liang","year":"2025","unstructured":"Liang M, Hou L, Liang J, Bao S (2025) Ameliorating motor performance and quality of life in Parkinson\u2019s disease: a comparison of deep brain stimulation and focused ultrasound surgery. Front Neurol 16:1449973. https:\/\/doi.org\/10.3389\/fneur.2025.1449973","journal-title":"Front Neurol"},{"key":"3142_CR139","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1007\/s00415-022-11221-9","volume":"269","author":"K Longardner","year":"2022","unstructured":"Longardner K, Merola A, Litvan I et al (2022) Differential impact of individual autonomic domains on clinical outcomes in Parkinson\u2019s disease. J Neurol 269:5510\u20135520. https:\/\/doi.org\/10.1007\/s00415-022-11221-9","journal-title":"J Neurol"},{"key":"3142_CR140","doi-asserted-by":"publisher","first-page":"42","DOI":"10.14802\/jmd.20079","volume":"14","author":"M Lubomski","year":"2021","unstructured":"Lubomski M, Davis RL, Sue CM (2021) Health-related quality of life for Parkinson\u2019s disease patients and their caregivers. JMD 14:42\u201352. https:\/\/doi.org\/10.14802\/jmd.20079","journal-title":"JMD"},{"key":"3142_CR141","doi-asserted-by":"publisher","unstructured":"Di Luca DG, Luo S, Liu H, et al (2023) Racial and ethnic differences in health-related quality of life for individuals with Parkinson disease across centers of excellence. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000207247","DOI":"10.1212\/WNL.0000000000207247"},{"key":"3142_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092191","volume":"13","author":"M Lungu","year":"2025","unstructured":"Lungu M, Oprea VD, Apostol LL et al (2025) Levodopa\u2013carbidopa\u2013entacapone intestinal gel for advanced Parkinson\u2019s disease\u2014results from a monocentric study evaluating both motor and non-motor manifestations. Biomedicines 13:2191. https:\/\/doi.org\/10.3390\/biomedicines13092191","journal-title":"Biomedicines"},{"key":"3142_CR143","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3171\/jns.2005.103.2.0252","volume":"103","author":"KE Lyons","year":"2005","unstructured":"Lyons KE, Pahwa R (2005) Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. J Neurosurg 103:252\u2013255. https:\/\/doi.org\/10.3171\/jns.2005.103.2.0252","journal-title":"J Neurosurg"},{"key":"3142_CR144","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2017.02.024","volume":"38","author":"T Maeda","year":"2017","unstructured":"Maeda T, Shimo Y, Chiu S-W et al (2017) Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson\u2019s disease patients from 35 medical centers. Parkinsonism Relat Disord 38:54\u201360. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.024","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR145","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.3390\/jcm13175081","volume":"13","author":"D Magano","year":"2024","unstructured":"Magano D, Taveira-Gomes T, Massano J, Barros AS (2024) Predicting quality of life in Parkinson\u2019s disease: a machine learning approach employing common clinical variables. J Clin Med 13:5081. https:\/\/doi.org\/10.3390\/jcm13175081","journal-title":"J Clin Med"},{"key":"3142_CR146","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-022-02560-1","volume":"22","author":"IA Malaty","year":"2022","unstructured":"Malaty IA, Martinez-Martin P, Chaudhuri KR et al (2022) Does the 5\u20132\u22121 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5\u20132-1-positive patients in 7 countries. BMC Neurol 22:35. https:\/\/doi.org\/10.1186\/s12883-022-02560-1","journal-title":"BMC Neurol"},{"key":"3142_CR147","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/JPD-2012-120103","volume":"2","author":"A Manson","year":"2012","unstructured":"Manson A, Stirpe P, Schrag A (2012) Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2:189\u2013198. https:\/\/doi.org\/10.3233\/JPD-2012-120103","journal-title":"J Parkinsons Dis"},{"key":"3142_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248968","volume":"16","author":"S Mantri","year":"2021","unstructured":"Mantri S, Klawson E, Albert S et al (2021) The experience of care partners of patients with Parkinson\u2019s disease psychosis. PLoS One 16:e0248968. https:\/\/doi.org\/10.1371\/journal.pone.0248968","journal-title":"PLoS One"},{"key":"3142_CR149","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1227\/neu.0000000000002518","volume":"93","author":"GA Maragkos","year":"2023","unstructured":"Maragkos GA, Kosyakovsky J, Zhao P et al (2023) Patient-reported outcomes after focused ultrasound thalamotomy for tremor-predominant Parkinson\u2019s disease. Neurosurgery 93:884\u2013891. https:\/\/doi.org\/10.1227\/neu.0000000000002518","journal-title":"Neurosurgery"},{"key":"3142_CR150","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/mds.21853","volume":"23","author":"C Marras","year":"2008","unstructured":"Marras C, McDermott MP, Rochon PA et al (2008) Predictors of deterioration in health\u2010related quality of life in Parkinson\u2019s disease: results from the DATATOP trial. Mov Disord 23:653\u2013659. https:\/\/doi.org\/10.1002\/mds.21853","journal-title":"Mov Disord"},{"key":"3142_CR151","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2011.05.006","volume":"310","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P (2011) The importance of non-motor disturbances to quality of life in Parkinson\u2019s disease. J Neurol Sci 310:12\u201316. https:\/\/doi.org\/10.1016\/j.jns.2011.05.006","journal-title":"J Neurol Sci"},{"key":"3142_CR152","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mds.26885","volume":"32","author":"P Martinez-Martin","year":"2017","unstructured":"Martinez-Martin P (2017) What is quality of life and how do we measure it? Relevance to Parkinson\u2019s disease and movement disorders. Mov Disord 32:382\u2013392. https:\/\/doi.org\/10.1002\/mds.26885","journal-title":"Mov Disord"},{"key":"3142_CR153","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11136-004-6253-y","volume":"14","author":"P Mart\u00ednez-Mart\u00edn","year":"2005","unstructured":"Mart\u00ednez-Mart\u00edn P, Benito-Le\u00f3n J, Alonso F et al (2005) Quality of life of caregivers in Parkinson\u2019s disease. Qual Life Res 14:463\u2013472. https:\/\/doi.org\/10.1007\/s11136-004-6253-y","journal-title":"Qual Life Res"},{"key":"3142_CR154","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11136-005-4181-0","volume":"15","author":"P Martinez-Martin","year":"2006","unstructured":"Martinez-Martin P, Catalan MJ, Benito-Leon J et al (2006) Impact of fatigue in Parkinson\u2019s disease: the fatigue impact scale for daily use (D-FIS). Qual Life Res 15:597\u2013606. https:\/\/doi.org\/10.1007\/s11136-005-4181-0","journal-title":"Qual Life Res"},{"key":"3142_CR155","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/mds.21355","volume":"22","author":"P Mart\u00ednez-Mart\u00edn","year":"2007","unstructured":"Mart\u00ednez-Mart\u00edn P, Forjaz MJ, Frades-Payo B et al (2007) Caregiver burden in Parkinson\u2019s disease. Mov Disord 22:924\u2013931. https:\/\/doi.org\/10.1002\/mds.21355","journal-title":"Mov Disord"},{"key":"3142_CR156","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/mds.22106","volume":"23","author":"P Martinez-Martin","year":"2008","unstructured":"Martinez-Martin P, Arroyo S, Rojo-Abuin JM et al (2008a) Burden, perceived health status, and mood among caregivers of Parkinson\u2019s disease patients. Mov Disord 23:1673\u20131680. https:\/\/doi.org\/10.1002\/mds.22106","journal-title":"Mov Disord"},{"key":"3142_CR157","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/mds.22202","volume":"23","author":"P Mart\u00ednez\u2010Martin","year":"2008","unstructured":"Mart\u00ednez\u2010Martin P, Carod\u2010Artal FJ, Da Silveira Ribeiro L et al (2008b) Longitudinal psychometric attributes, responsiveness, and importance of change: an approach using the SCOPA\u2010Psychosocial questionnaire. Mov Disord 23:1516\u20131523. https:\/\/doi.org\/10.1002\/mds.22202","journal-title":"Mov Disord"},{"key":"3142_CR158","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Jeukens-Visser M, Lyons KE et al (2011a) Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord 26:2371\u20132380. https:\/\/doi.org\/10.1002\/mds.23834","journal-title":"Mov Disord"},{"key":"3142_CR159","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Mart\u00ednez-Martin","year":"2011","unstructured":"Mart\u00ednez-Martin P, Jeukens-Visser M, Lyons KE et al (2011b) Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord 26:2371\u20132380. https:\/\/doi.org\/10.1002\/mds.23834","journal-title":"Mov Disord"},{"key":"3142_CR160","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/erp.11.106","volume":"12","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ (2012) Quality of life and burden in caregivers for patients with Parkinson\u2019s disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res 12:221\u2013230. https:\/\/doi.org\/10.1586\/erp.11.106","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3142_CR161","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/ene.12349","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2014","unstructured":"Mart\u00ednez-Mart\u00edn P, Rodr\u00edguez-Bl\u00e1zquez C, Forjaz MJ et al (2014) Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson\u2019s disease patients. Euro J Neurol 21:519\u2013524. https:\/\/doi.org\/10.1111\/ene.12349","journal-title":"Euro J Neurol"},{"key":"3142_CR162","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R et al (2015) Euro Inf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord 30:510\u2013516. https:\/\/doi.org\/10.1002\/mds.26067","journal-title":"Mov Disord"},{"key":"3142_CR163","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jnnp-2014-310189","volume":"87","author":"R Martinez-Fernandez","year":"2016","unstructured":"Martinez-Fernandez R, Pelissier P, Quesada J-L et al (2016a) Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 87:311\u2013318. https:\/\/doi.org\/10.1136\/jnnp-2014-310189","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3142_CR164","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2016","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Schmitt E, Martinez-Martin P, Krack P (2016b) The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations. Mov Disord 31:1080\u20131094. https:\/\/doi.org\/10.1002\/mds.26731","journal-title":"Mov Disord"},{"key":"3142_CR165","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(17)30403-9","volume":"17","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2018","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Rodr\u00edguez-Rojas R, Del \u00c1lamo M et al (2018) Focused ultrasound subthalamotomy in patients with asymmetric Parkinson\u2019s disease: a pilot study. Lancet Neurol 17:54\u201363. https:\/\/doi.org\/10.1016\/S1474-4422(17)30403-9","journal-title":"Lancet Neurol"},{"key":"3142_CR166","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/NEJMoa2016311","volume":"383","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2020","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, M\u00e1\u00f1ez-Mir\u00f3 JU, Rodr\u00edguez-Rojas R et al (2020) Randomized trial of focused ultrasound subthalamotomy for Parkinson\u2019s disease. N Engl J Med 383:2501\u20132513. https:\/\/doi.org\/10.1056\/NEJMoa2016311","journal-title":"N Engl J Med"},{"key":"3142_CR167","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/mds.10044","volume":"17","author":"P Mart\u00ednez-Mart\u00edn","year":"2002","unstructured":"Mart\u00ednez-Mart\u00edn P, Valldeoriola F, Tolosa E et al (2002) Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson\u2019s disease. Mov Disord 17:372\u2013377. https:\/\/doi.org\/10.1002\/mds.10044","journal-title":"Mov Disord"},{"key":"3142_CR168","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Natera-Villalba E, M\u00e1\u00f1ez Mir\u00f3 JU, et al (2023) Prospective long-term follow-up of focused ultrasound unilateral subthalamotomy for Parkinson disease. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000206771","DOI":"10.1212\/WNL.0000000000206771"},{"key":"3142_CR169","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.1220","volume":"81","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2024","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Natera-Villalba E, Rodr\u00edguez-Rojas R et al (2024) Staged bilateral MRI-guided focused ultrasound subthalamotomy for Parkinson disease. JAMA Neurol 81:638. https:\/\/doi.org\/10.1001\/jamaneurol.2024.1220","journal-title":"JAMA Neurol"},{"key":"3142_CR170","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.parkreldis.2019.06.001","volume":"65","author":"R Mehanna","year":"2019","unstructured":"Mehanna R, Jankovic J (2019) Young-onset Parkinson\u2019s disease: its unique features and their impact on quality of life. Parkinsonism Relat Disord 65:39\u201348. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00194-7","volume":"7","author":"B Meira","year":"2021","unstructured":"Meira B, Degos B, Corsetti E et al (2021) Long-term effect of apomorphine infusion in advanced Parkinson\u2019s Disease: a real-life study. NPJ Parkinsons Dis 7:50. https:\/\/doi.org\/10.1038\/s41531-021-00194-7","journal-title":"NPJ Parkinsons Dis"},{"key":"3142_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2517","volume":"12","author":"D Meng","year":"2022","unstructured":"Meng D, Jin Z, Gao L et al (2022) The quality of life in patients with Parkinson\u2019s disease: focus on gender difference. Brain Behavior 12:e2517. https:\/\/doi.org\/10.1002\/brb3.2517","journal-title":"Brain Behavior"},{"key":"3142_CR173","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2016.09.013","volume":"33","author":"A Merola","year":"2016","unstructured":"Merola A, Romagnolo A, Rosso M et al (2016) Orthostatic hypotension in Parkinson\u2019s disease: does it matter if asymptomatic? Parkinsonism Relat Disord 33:65\u201371. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.09.013","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR174","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/mds.27268","volume":"33","author":"A Merola","year":"2018","unstructured":"Merola A, Romagnolo A, Rosso M et al (2018) Autonomic dysfunction in Parkinson\u2019s disease: a prospective cohort study. Mov Disord 33:391\u2013397. https:\/\/doi.org\/10.1002\/mds.27268","journal-title":"Mov Disord"},{"key":"3142_CR175","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/08919887231168404","volume":"36","author":"RK Merritt","year":"2023","unstructured":"Merritt RK, Hotham S, Schrag A (2023) Support needs in carers of people with Parkinson\u2019s from early to later stages: a qualitative study with 36 carers in 11 European countries. J Geriatr Psychiatry Neurol 36:505\u2013510. https:\/\/doi.org\/10.1177\/08919887231168404","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"3142_CR176","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/(SICI)1099-1166(199603)11:3<263::AID-GPS316>3.0.CO;2-P","volume":"11","author":"E Miller","year":"1996","unstructured":"Miller E, Berrios GE, Politynska BE (1996) Caring for someone with Parkinson\u2019s disease: factors that contribute to distress. Int J Geriatr Psychiatry 11:263\u2013268https:\/\/doi.org\/10.1002\/(SICI)1099-1166(199603)11:3<263::AID-GPS316>3.0.CO;2-P","journal-title":"Int J Geriatr Psychiatry"},{"key":"3142_CR177","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10143-024-02948-2","volume":"47","author":"JDS Monteiro","year":"2024","unstructured":"Monteiro JDS, Silva EBB, De Oliveira RR et al (2024) Magnetic resonance-guided focused ultrasound ventral intermediate thalamotomy for Tremor-Dominant Parkinson\u2019s disease: a systematic review and meta-analysis. Neurosurg Rev 47:701. https:\/\/doi.org\/10.1007\/s10143-024-02948-2","journal-title":"Neurosurg Rev"},{"key":"3142_CR178","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-005-0285-5","volume":"112","author":"O Moore","year":"2005","unstructured":"Moore O, Kreitler S, Ehrenfeld M, Giladi N (2005) Quality of life and gender identity in Parkinson\u2019s disease. J Neural Transm 112:1511\u20131522. https:\/\/doi.org\/10.1007\/s00702-005-0285-5","journal-title":"J Neural Transm"},{"key":"3142_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123253","volume":"466","author":"R Morimoto","year":"2024","unstructured":"Morimoto R, Kitagawa K, Iijima M (2024) Importance of focusing on subjective symptoms to maintain quality of life in patients with Parkinson\u2019s disease for over 5 years. J Neurol Sci 466:123253. https:\/\/doi.org\/10.1016\/j.jns.2024.123253","journal-title":"J Neurol Sci"},{"key":"3142_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/190901","volume":"2012","author":"D Morley","year":"2012","unstructured":"Morley D, Dummett S, Peters M et al (2012) Factors Influencing quality of life in caregivers of people with Parkinson\u2019s disease and implications for clinical guidelines. Parkinson\u2019s Dis 2012:1\u20136. https:\/\/doi.org\/10.1155\/2012\/190901","journal-title":"Parkinson\u2019s Dis"},{"key":"3142_CR181","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/08919887251346495","volume":"39","author":"JF Morley","year":"2026","unstructured":"Morley JF, Subramanian I, Farahnik J et al (2026) Physical activity, patient-reported outcomes, and quality of life in Parkinson\u2019s disease. J Geriatr Psychiatry Neurol 39:14\u201323. https:\/\/doi.org\/10.1177\/08919887251346495","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"3142_CR182","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/mds.22735","volume":"25","author":"E Moro","year":"2010","unstructured":"Moro E, Lozano AM, Pollak P et al (2010) Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson\u2019s disease. Mov Disord 25:578\u2013586. https:\/\/doi.org\/10.1002\/mds.22735","journal-title":"Mov Disord"},{"key":"3142_CR183","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","volume":"19","author":"B M\u00fcller","year":"2013","unstructured":"M\u00fcller B, Assmus J, Herlofson K et al (2013) Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson\u2019s disease. Parkinsonism Relat Disord 19:1027\u20131032. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.07.010","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR184","doi-asserted-by":"publisher","first-page":"16020","DOI":"10.1038\/npjparkd.2016.20","volume":"2","author":"M Murata","year":"2016","unstructured":"Murata M, Mihara M, Hasegawa K et al (2016) Efficacy and safety of levodopa\u2013carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson\u2019s disease patients. NPJ Parkinson\u2019s Dis 2:16020. https:\/\/doi.org\/10.1038\/npjparkd.2016.20","journal-title":"NPJ Parkinson\u2019s Dis"},{"key":"3142_CR185","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mdc3.14199","volume":"11","author":"S Murcia Carretero","year":"2024","unstructured":"Murcia Carretero S, Petermann K, Debove I et al (2024) Quality of life after deep brain stimulation in Parkinson\u2019s disease: Does the target matter? Mov Disord Clin Pract 11:1379\u20131387. https:\/\/doi.org\/10.1002\/mdc3.14199","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR186","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/mdc3.13700","volume":"10","author":"K Nagaki","year":"2023","unstructured":"Nagaki K, Nakagawa R, Ishido M et al (2023) Impact of Parkinson\u2019s disease on caregiver quality of life in Japan. Mov Disord Clin Pract 10:658\u2013663. https:\/\/doi.org\/10.1002\/mdc3.13700","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR187","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.4470","author":"JP Ney","year":"2025","unstructured":"Ney JP, Steinmetz JD, Anderson-benge E et al (2025) US burden of disorders affecting the nervous system: From the Global Burden of Disease 2021 Study. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.4470","journal-title":"JAMA Neurol"},{"key":"3142_CR188","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(12)70264-8","volume":"12","author":"VJ Odekerken","year":"2013","unstructured":"Odekerken VJ, Van Laar T, Staal MJ et al (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson\u2019s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12:37\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(12)70264-8","journal-title":"Lancet Neurol"},{"key":"3142_CR189","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(11)70308-8","volume":"11","author":"MS Okun","year":"2012","unstructured":"Okun MS, Gallo BV, Mandybur G et al (2012) Subthalamic deep brain stimulation with a constant-current device in Parkinson\u2019s disease: an open-label randomised controlled trial. Lancet Neurol 11:140\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(11)70308-8","journal-title":"Lancet Neurol"},{"key":"3142_CR190","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"3142_CR191","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205100","volume":"13","author":"N Ongun","year":"2018","unstructured":"Ongun N (2018) Does nutritional status affect Parkinson\u2019s disease features and quality of life? PLoS One 13:e0205100. https:\/\/doi.org\/10.1371\/journal.pone.0205100","journal-title":"PLoS One"},{"key":"3142_CR192","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/JPD-160996","volume":"7","author":"C Ossig","year":"2017","unstructured":"Ossig C, Sippel D, Fauser M et al (2017) Timing and kinetics of nonmotor fluctuations in advanced Parkinson\u2019s disease. J Parkinsons Dis 7:325\u2013330. https:\/\/doi.org\/10.3233\/JPD-160996","journal-title":"J Parkinsons Dis"},{"key":"3142_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040254","volume":"11","author":"M \u00d6thman","year":"2021","unstructured":"\u00d6thman M, Widman E, Nygren I, Nyholm D (2021) Initial experience of the Levodopa\u2013Entacapone\u2013Carbidopa intestinal gel in clinical practice. J Pers Med 11:254. https:\/\/doi.org\/10.3390\/jpm11040254","journal-title":"J Pers Med"},{"key":"3142_CR194","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1176\/appi.neuropsych.11100315","volume":"24","author":"B Ozdilek","year":"2012","unstructured":"Ozdilek B, Gunal DI (2012) Motor and non-motor symptoms in Turkish patients with Parkinson\u2019s disease affecting family caregiver burden and quality of life. J Neuropsychiatry Clin Neurosci 24:478\u2013483. https:\/\/doi.org\/10.1176\/appi.neuropsych.11100315","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3142_CR195","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013611","volume":"7","author":"TE Page","year":"2017","unstructured":"Page TE, Farina N, Brown A et al (2017) Instruments measuring the disease-specific quality of life of family carers of people with neurodegenerative diseases: a systematic review. BMJ Open 7:e013611. https:\/\/doi.org\/10.1136\/bmjopen-2016-013611","journal-title":"BMJ Open"},{"key":"3142_CR196","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.parkreldis.2003.11.002","volume":"10","author":"PK Pal","year":"2004","unstructured":"Pal PK, Thennarasu K, Fleming J et al (2004) Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson\u2019s disease and in their caregivers. Parkinsonism Relat Disord 10:157\u2013168. https:\/\/doi.org\/10.1016\/j.parkreldis.2003.11.002","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR197","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.06.002","volume":"29","author":"SE P\u00e5lhagen","year":"2016","unstructured":"P\u00e5lhagen SE, Sydow O, Johansson A et al (2016) Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson\u2019s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord 29:17\u201323. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.06.002","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR198","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5870","volume":"38","author":"K Perepezko","year":"2023","unstructured":"Perepezko K, Hinkle JT, Forbes EJ et al (2023) The impact of caregiving on quality of life in Parkinson\u2019s disease: a systematic review. Int J Geriatr Psychiatry 38:e5870. https:\/\/doi.org\/10.1002\/gps.5870","journal-title":"Int J Geriatr Psychiatry"},{"key":"3142_CR199","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/ene.13466","volume":"24","author":"S Perez\u2010Lloret","year":"2017","unstructured":"Perez\u2010Lloret S, Negre\u2010Pages L, Damier P et al (2017) L\u2010 DOPA \u2010induced dyskinesias, motor fluctuations and health\u2010related quality of life: the COPARK survey. Eur J Neurol 24:1532\u20131538. https:\/\/doi.org\/10.1111\/ene.13466","journal-title":"Eur J Neurol"},{"key":"3142_CR200","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocn.2013.02.032","volume":"21","author":"AL Phu","year":"2014","unstructured":"Phu AL, Xu Z, Brakoulias V et al (2014) Effect of impulse control disorders on disability and quality of life in Parkinson\u2019s disease patients. J Clin Neurosci 21:63\u201366. https:\/\/doi.org\/10.1016\/j.jocn.2013.02.032","journal-title":"J Clin Neurosci"},{"key":"3142_CR201","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s11136-024-03703-2","volume":"33","author":"JS Pigott","year":"2024","unstructured":"Pigott JS, Armstrong M, Davies N et al (2024) Factors associated with self-rated health in people with late-stage Parkinson\u2019s and cognitive impairment. Qual Life Res 33:2439\u20132452. https:\/\/doi.org\/10.1007\/s11136-024-03703-2","journal-title":"Qual Life Res"},{"key":"3142_CR202","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11136-015-1071-y","volume":"25","author":"M Pillas","year":"2016","unstructured":"Pillas M, Selai C, Quinn NP et al (2016) Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Qual Life Res 25:81\u201388. https:\/\/doi.org\/10.1007\/s11136-015-1071-y","journal-title":"Qual Life Res"},{"key":"3142_CR203","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/mds.26877","volume":"32","author":"M Pillas","year":"2017","unstructured":"Pillas M, Selai C, Schrag A (2017) Rasch analysis of the carers quality of life questionnaire for parkinsonism. Mov Disord 32:463\u2013466. https:\/\/doi.org\/10.1002\/mds.26877","journal-title":"Mov Disord"},{"key":"3142_CR204","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/mds.22617","volume":"24","author":"EK Plowman\u2010Prine","year":"2009","unstructured":"Plowman\u2010Prine EK, Sapienza CM, Okun MS et al (2009) The relationship between quality of life and swallowing in Parkinson\u2019s disease. Mov Disord 24:1352\u20131358. https:\/\/doi.org\/10.1002\/mds.22617","journal-title":"Mov Disord"},{"key":"3142_CR205","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/mds.23467","volume":"26","author":"B Post","year":"2011","unstructured":"Post B, Muslimovic D, Van Geloven N et al (2011) Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson\u2019s disease. Mov Disord 26:449\u2013456. https:\/\/doi.org\/10.1002\/mds.23467","journal-title":"Mov Disord"},{"key":"3142_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1183289","volume":"10","author":"T Prell","year":"2023","unstructured":"Prell T, Sch\u00f6nenberg A, Heimrich KG (2023) The impact of loneliness on quality of life in people with Parkinson\u2019s disease: results from the survey of health, ageing and retirement in Europe. Front Med 10:1183289. https:\/\/doi.org\/10.3389\/fmed.2023.1183289","journal-title":"Front Med"},{"key":"3142_CR207","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/mds.21667","volume":"23","author":"S Rahman","year":"2008","unstructured":"Rahman S, Griffin HJ, Quinn NP, Jahanshahi M (2008) Quality of life in Parkinson\u2019s disease: the relative importance of the symptoms. Mov Disord 23:1428\u20131434. https:\/\/doi.org\/10.1002\/mds.21667","journal-title":"Mov Disord"},{"key":"3142_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01093-x","volume":"11","author":"A Ramirez-Zamora","year":"2025","unstructured":"Ramirez-Zamora A, Okun MS, Kukreja P, Hu W (2025) Parkinson\u2019s Disease quality of life at 12 months comparing invasive device-aided therapy with oral treatment. Npj Parkinsons Dis 11:235. https:\/\/doi.org\/10.1038\/s41531-025-01093-x","journal-title":"Npj Parkinsons Dis"},{"key":"3142_CR209","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27485","volume":"6","author":"R Rashid","year":"2023","unstructured":"Rashid R, Aamodt WW, Horn S, Dahodwala N (2023) Association of caregiver depression risk with patient outcomes in Parkinson disease. JAMA Netw Open 6:e2327485. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27485","journal-title":"JAMA Netw Open"},{"key":"3142_CR210","first-page":"17","volume":"54","author":"J Ray","year":"2006","unstructured":"Ray J, Das SK, Gangopadhya PK, Roy T (2006) Quality of life in Parkinson\u2019s disease\u2013Indian scenario. J Assoc Physicians India 54:17\u201321","journal-title":"J Assoc Physicians India"},{"key":"3142_CR211","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02990-4","author":"M Regensburger","year":"2025","unstructured":"Regensburger M, Csoti I, Jost WH et al (2025) Motor and non-motor fluctuations in Parkinson\u2019s disease: the knowns and unknowns of current therapeutic approaches. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-025-02990-4","journal-title":"J Neural Transm"},{"key":"3142_CR212","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/JPD-150747","volume":"6","author":"I Rieu","year":"2016","unstructured":"Rieu I, Houeto JL, Pereira B et al (2016) Impact of mood and behavioral disorders on quality of life in Parkinson\u2019s disease. J Parkinson\u2019s Dis 6:267\u2013277. https:\/\/doi.org\/10.3233\/JPD-150747","journal-title":"J Parkinson\u2019s Dis"},{"key":"3142_CR213","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1212\/wnl.43.8.1459","volume":"43","author":"DE Riley","year":"1993","unstructured":"Riley DE, Lang AE (1993) The spectrum of levodopa-related fluctuations in Parkinson\u2019s disease. Neurology 43:1459\u20131464. https:\/\/doi.org\/10.1212\/wnl.43.8.1459","journal-title":"Neurology"},{"key":"3142_CR214","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1002\/mds.21427","volume":"22","author":"JP Rodrigues","year":"2007","unstructured":"Rodrigues JP, Walters SE, Watson P et al (2007) Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson\u2019s disease. Mov Disord 22:1866\u20131870. https:\/\/doi.org\/10.1002\/mds.21427","journal-title":"Mov Disord"},{"key":"3142_CR215","doi-asserted-by":"publisher","first-page":"175628642513369","DOI":"10.1177\/17562864251336903","volume":"18","author":"J Rodr\u00edguez-Antig\u00fcedad","year":"2025","unstructured":"Rodr\u00edguez-Antig\u00fcedad J, Olmedo-Saura G, Pagonabarraga J et al (2025) Approaches for treating neuropsychiatric symptoms in Parkinson\u2019s disease: a narrative review. Ther Adv Neurol Disord 18:17562864251336904. https:\/\/doi.org\/10.1177\/17562864251336903","journal-title":"Ther Adv Neurol Disord"},{"key":"3142_CR216","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1600-0404.2008.01114.x","volume":"119","author":"JH Roh","year":"2009","unstructured":"Roh JH, Kim B-J, Jang J-H et al (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson\u2019s disease. Acta Neurol Scand 119:397\u2013403. https:\/\/doi.org\/10.1111\/j.1600-0404.2008.01114.x","journal-title":"Acta Neurol Scand"},{"key":"3142_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9475026","volume":"2021","author":"K Rosqvist","year":"2021","unstructured":"Rosqvist K, Kylberg M, L\u00f6fqvist C et al (2021) Perspectives on care for late-stage Parkinson\u2019s disease. Parkinson Dis 2021:1\u201311. https:\/\/doi.org\/10.1155\/2021\/9475026","journal-title":"Parkinson Dis"},{"key":"3142_CR218","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12010111","volume":"12","author":"K Rosqvist","year":"2022","unstructured":"Rosqvist K, Schrag A, Odin P, the CLaSP Consortium (2022) Caregiver burden and quality of life in late stage Parkinson\u2019s disease. Brain Sci 12:111. https:\/\/doi.org\/10.3390\/brainsci12010111","journal-title":"Brain Sci"},{"key":"3142_CR219","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/neuros\/nyy037","volume":"82","author":"A Rughani","year":"2018","unstructured":"Rughani A, Schwalb JM, Sidiropoulos C et al (2018) Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson\u2019s disease: executive summary. Neurosurgery 82:753\u2013756. https:\/\/doi.org\/10.1093\/neuros\/nyy037","journal-title":"Neurosurgery"},{"key":"3142_CR220","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2019.07.031","volume":"66","author":"D Santos Garc\u00eda","year":"2019","unstructured":"Santos Garc\u00eda D, De Deus Fonticoba T, Su\u00e1rez Castro E et al (2019) Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson\u2019s disease patients: results from the COPPADIS study cohort. Parkinsonism Relat Disord 66:151\u2013157. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.031","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00256-w","volume":"7","author":"D Santos Garc\u00eda","year":"2021","unstructured":"Santos Garc\u00eda D, De Deus Fonticoba T, Cores C et al (2021) Predictors of clinically significant quality of life impairment in Parkinson\u2019s Disease. Npj Parkinsons Dis 7:118. https:\/\/doi.org\/10.1038\/s41531-021-00256-w","journal-title":"Npj Parkinsons Dis"},{"key":"3142_CR222","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/mdc3.14056","volume":"11","author":"D Santos\u2010Garc\u00eda","year":"2024","unstructured":"Santos\u2010Garc\u00eda D, De Deus T, Cores C et al (2024) Levodopa\u2010induced dyskinesias are frequent and impact quality of life in Parkinson\u2019s disease: a 5\u2010year follow\u2010up study. Mov Disord Clin Pract 11:830\u2013849. https:\/\/doi.org\/10.1002\/mdc3.14056","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR223","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16535","volume":"32","author":"D Santos\u2010Garc\u00eda","year":"2025","unstructured":"Santos\u2010Garc\u00eda D, L\u00f3pez\u2010Manzanares L, Muro I et al (2025) Effectiveness and safety of levodopa\u2013entacapone\u2013carbidopa infusion in Parkinson disease: a real\u2010world data study. Eur J Neurol 32:e16535. https:\/\/doi.org\/10.1111\/ene.16535","journal-title":"Eur J Neurol"},{"key":"3142_CR224","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2013.07.005","volume":"332","author":"D Santos-Garc\u00eda","year":"2013","unstructured":"Santos-Garc\u00eda D, De La Fuente-Fern\u00e1ndez R (2013) Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson\u2019s disease. J Neurol Sci 332:136\u2013140. https:\/\/doi.org\/10.1016\/j.jns.2013.07.005","journal-title":"J Neurol Sci"},{"key":"3142_CR225","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ane.12305","volume":"131","author":"D Santos-Garc\u00eda","year":"2015","unstructured":"Santos-Garc\u00eda D, De La Fuente-Fern\u00e1ndez R (2015) Factors contributing to caregivers\u2019 stress and burden in Parkinson\u2019s disease. Acta Neurol Scand 131:203\u2013210. https:\/\/doi.org\/10.1111\/ane.12305","journal-title":"Acta Neurol Scand"},{"key":"3142_CR226","doi-asserted-by":"publisher","unstructured":"Santos-Garc\u00eda D, Solleiro \u00c1, Gonz\u00e1lez-Ortega G, et al (2025) Impact of device-aided therapies on quality of life in patients with Parkinson\u2019s disease. A comparative multicenter observational study. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-025-03066-z","DOI":"10.1007\/s00702-025-03066-z"},{"key":"3142_CR227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/219149","volume":"2015","author":"I Schlesinger","year":"2015","unstructured":"Schlesinger I, Eran A, Sinai A et al (2015) MRI guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson\u2019s disease. Parkinson Dis 2015:1\u20134. https:\/\/doi.org\/10.1155\/2015\/219149","journal-title":"Parkinson Dis"},{"key":"3142_CR228","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2006.05.030","volume":"248","author":"A Schrag","year":"2006","unstructured":"Schrag A (2006) Quality of life and depression in Parkinson\u2019s disease. J Neurol Sci 248:151\u2013157. https:\/\/doi.org\/10.1016\/j.jns.2006.05.030","journal-title":"J Neurol Sci"},{"key":"3142_CR229","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A","volume":"15","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson\u2019s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112\u20131118.https:\/\/doi.org\/10.1002\/1531-8257(200011)15:6%3C1112::AID-MDS1008%3E3.0.CO;2-A","journal-title":"Mov Disord"},{"key":"3142_CR230","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","volume":"12","author":"A Schrag","year":"2006","unstructured":"Schrag A, Hovris A, Morley D et al (2006) Caregiver-burden in parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 12:35\u201341. https:\/\/doi.org\/10.1016\/j.parkreldis.2005.06.011","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR231","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/mds.22438","volume":"24","author":"A Schrag","year":"2009","unstructured":"Schrag A, Spottke A, Quinn NP, Dodel R (2009) Comparative responsiveness of Parkinson\u2019s disease scales to change over time. Mov Disord 24:813\u2013818. https:\/\/doi.org\/10.1002\/mds.22438","journal-title":"Mov Disord"},{"key":"3142_CR232","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov Disord 32:283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov Disord"},{"key":"3142_CR233","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0212-1","volume":"14","author":"JM Sheard","year":"2014","unstructured":"Sheard JM, Ash S, Mellick GD et al (2014) Improved nutritional status is related to improved quality of life in Parkinson\u2019s disease. BMC Neurol 14:212. https:\/\/doi.org\/10.1186\/s12883-014-0212-1","journal-title":"BMC Neurol"},{"key":"3142_CR234","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/mds.20786","volume":"21","author":"A Siderowf","year":"2006","unstructured":"Siderowf A, Jaggi JL, Xie SX et al (2006) Long\u2010term effects of bilateral subthalamic nucleus stimulation on health\u2010related quality of life in advanced Parkinson\u2019s disease. Mov Disord 21:746\u2013753. https:\/\/doi.org\/10.1002\/mds.20786","journal-title":"Mov Disord"},{"key":"3142_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11121566","volume":"11","author":"MA Simu","year":"2021","unstructured":"Simu MA, Jianu DC, Dulamea AO et al (2021) Advanced Parkinson\u2019s disease treatment simplification and long-term outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian subanalysis. Brain Sci 11:1566. https:\/\/doi.org\/10.3390\/brainsci11121566","journal-title":"Brain Sci"},{"key":"3142_CR236","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jns.2015.04.013","volume":"353","author":"M Skorvanek","year":"2015","unstructured":"Skorvanek M, Rosenberger J, Minar M et al (2015) Relationship between the non-motor items of the MDS\u2013UPDRS and quality of life in patients with Parkinson\u2019s disease. J Neurol Sci 353:87\u201391. https:\/\/doi.org\/10.1016\/j.jns.2015.04.013","journal-title":"J Neurol Sci"},{"key":"3142_CR237","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.parkreldis.2005.04.006","volume":"11","author":"J S\u0142awek","year":"2005","unstructured":"S\u0142awek J, Derejko M, Lass P (2005) Factors affecting the quality of life of patients with idiopathic Parkinson\u2019s disease-a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord 11:465\u2013468. https:\/\/doi.org\/10.1016\/j.parkreldis.2005.04.006","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR238","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C et al (2015) Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis 5:165\u2013174. https:\/\/doi.org\/10.3233\/JPD-140456","journal-title":"J Parkinsons Dis"},{"key":"3142_CR239","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1753","volume":"10","author":"ER Smith","year":"2020","unstructured":"Smith ER, Perrin PB, Tyler CM et al (2020) Cross-cultural differences in Parkinson\u2019s disease caregiving and burden between the United States and Mexico. Brain Behav 10:e01753. https:\/\/doi.org\/10.1002\/brb3.1753","journal-title":"Brain Behav"},{"key":"3142_CR240","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2010.08.012","volume":"17","author":"S-E Soh","year":"2011","unstructured":"Soh S-E, Morris ME, McGinley JL (2011) Determinants of health-related quality of life in Parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord 17:1\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.08.012","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR241","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"3142_CR242","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00415-025-13123-y","volume":"272","author":"M Soileau","year":"2025","unstructured":"Soileau M, Kumar R, Parab A et al (2025) Patients\u2019 experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa\/foscarbidopa in Parkinson\u2019s disease. J Neurol 272:416. https:\/\/doi.org\/10.1007\/s00415-025-13123-y","journal-title":"J Neurol"},{"key":"3142_CR243","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4103\/aian.aian_902_21","volume":"25","author":"R Soumiya","year":"2022","unstructured":"Soumiya R, Paul BS, Aggarwal R, Paul G (2022) Neuropathy in Parkinson\u2019s disease: risk determinants and impact on quality of life. Ann Indian Acad Neurol 25:428\u2013432. https:\/\/doi.org\/10.4103\/aian.aian_902_21","journal-title":"Ann Indian Acad Neurol"},{"key":"3142_CR244","doi-asserted-by":"publisher","unstructured":"Sperling SA, Shah BB, Barrett MJ, et al (2018) Focused ultrasound thalamotomy in Parkinson disease: nonmotor outcomes and quality of life. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000006279","DOI":"10.1212\/WNL.0000000000006279"},{"key":"3142_CR245","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mdc3.13239","volume":"8","author":"DG Standaert","year":"2021","unstructured":"Standaert DG, Aldred J, Anca-Herschkovitsch M et al (2021) DUOGLOBE: one-year outcomes in a real-world study of levodopa carbidopa intestinal gel for Parkinson\u2019s disease. Mov Disord Clin Pract 8:1061\u20131074. https:\/\/doi.org\/10.1002\/mdc3.13239","journal-title":"Mov Disord Clin Pract"},{"key":"3142_CR246","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.3373","volume":"82","author":"PA Starr","year":"2025","unstructured":"Starr PA, Shivacharan RS, Goldberg E et al (2025) Five-year outcomes from deep brain stimulation of the subthalamic nucleus for Parkinson disease. JAMA Neurol 82:1181. https:\/\/doi.org\/10.1001\/jamaneurol.2025.3373","journal-title":"JAMA Neurol"},{"key":"3142_CR247","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80:800\u2013809. https:\/\/doi.org\/10.1212\/WNL.0b013e318285c0ed","journal-title":"Neurology"},{"key":"3142_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-00128-9","volume":"6","author":"I Subramanian","year":"2020","unstructured":"Subramanian I, Farahnik J, Mischley LK (2020) Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. Npj Parkinsons Dis 6:28. https:\/\/doi.org\/10.1038\/s41531-020-00128-9","journal-title":"Npj Parkinsons Dis"},{"key":"3142_CR249","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2017.0204","volume":"9","author":"Q Sun","year":"2018","unstructured":"Sun Q, Wang T, Jiang T-F et al (2018) Clinical profile of Chinese long-term Parkinson\u2019s Disease survivors with 10 years of disease duration and beyond. Aging Dis 9:8. https:\/\/doi.org\/10.14336\/AD.2017.0204","journal-title":"Aging Dis"},{"key":"3142_CR250","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/mds.20817","volume":"21","author":"Y Suzukamo","year":"2006","unstructured":"Suzukamo Y, Ohbu S, Kondo T et al (2006) Psychological adjustment has a greater effect on health\u2010related quality of life than on severity of disease in Parkinson\u2019s disease. Mov Disord 21:761\u2013766. https:\/\/doi.org\/10.1002\/mds.20817","journal-title":"Mov Disord"},{"key":"3142_CR251","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54299-z","volume":"14","author":"S Szatm\u00e1ri","year":"2024","unstructured":"Szatm\u00e1ri S, Sz\u00e1sz JA, Orb\u00e1n-Kis K et al (2024) Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson\u2019s disease patients. Sci Rep 14:3676. https:\/\/doi.org\/10.1038\/s41598-024-54299-z","journal-title":"Sci Rep"},{"key":"3142_CR252","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.parkreldis.2013.02.014","volume":"19","author":"H Tanji","year":"2013","unstructured":"Tanji H, Koyama S, Wada M et al (2013) Comparison of caregiver strain in Parkinson\u2019s disease between Yamagata, Japan, and Maryland, The United States. Parkinsonism Relat Disord 19:628\u2013633. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.02.014","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR253","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","volume":"391","author":"CM Tanner","year":"2024","unstructured":"Tanner CM, Ostrem JL (2024) Parkinson\u2019s disease. N Engl J Med 391:442\u2013452. https:\/\/doi.org\/10.1056\/NEJMra2401857","journal-title":"N Engl J Med"},{"key":"3142_CR254","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJM199603283341306","volume":"334","author":"MA Testa","year":"1996","unstructured":"Testa MA, Simonson DC (1996) Assessment of quality-of-life outcomes. N Engl J Med 334:835\u2013840. https:\/\/doi.org\/10.1056\/NEJM199603283341306","journal-title":"N Engl J Med"},{"key":"3142_CR255","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02074-2","volume":"21","author":"A Thach","year":"2021","unstructured":"Thach A, Jones E, Pappert E et al (2021) Real-world assessment of the impact of \u201cOFF\u201d episodes on health-related quality of life among patients with Parkinson\u2019s disease in the United States. BMC Neurol 21:46. https:\/\/doi.org\/10.1186\/s12883-021-02074-2","journal-title":"BMC Neurol"},{"key":"3142_CR256","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mds.10010","volume":"17","author":"The Global Parkinson\u2019s Disease Survey (GPDS) Steering Committee","year":"2002","unstructured":"The Global Parkinson\u2019s Disease Survey (GPDS) Steering Committee (2002) Factors impacting on quality of life in Parkinson\u2019s disease: results from an international survey. Mov Disord 17:60\u201367. https:\/\/doi.org\/10.1002\/mds.10010","journal-title":"Mov Disord"},{"key":"3142_CR257","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208028","volume":"102","author":"MH Tosin","year":"2024","unstructured":"Tosin MH, Goetz CG, Stebbins GT (2024) Patient with Parkinson disease and care partner perceptions of key domains affecting health-related quality of life: systematic review. Neurology 102:e208028. https:\/\/doi.org\/10.1212\/WNL.0000000000208028","journal-title":"Neurology"},{"key":"3142_CR258","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.parkreldis.2020.05.036","volume":"77","author":"I Trang","year":"2020","unstructured":"Trang I, Katz M, Galifianakis N et al (2020) Predictors of general and health-related quality of life in Parkinson\u2019s disease and related disorders including caregiver perspectives. Parkinsonism Relat Disord 77:5\u201310. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.036","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR259","doi-asserted-by":"publisher","unstructured":"Tykocki T, Szalecki K, Koziara H, et al (2012) Quality of life and depressive symptoms in parkinson\u2019s disease after subthalamic deep brain stimulation: a 2-year follow-up study. Turk Neurosurg. https:\/\/doi.org\/10.5137\/1019-5149.JTN.7184-12.1","DOI":"10.5137\/1019-5149.JTN.7184-12.1"},{"key":"3142_CR260","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/587302","volume":"2014","author":"P Valkovic","year":"2014","unstructured":"Valkovic P, Harsany J, Hanakova M et al (2014) Nonmotor symptoms in early- and advanced-stage Parkinson\u2019s disease patients on dopaminergic therapy: how do they correlate with quality of life? ISRN Neurol 2014:1\u20134. https:\/\/doi.org\/10.1155\/2014\/587302","journal-title":"ISRN Neurol"},{"key":"3142_CR261","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136541","volume":"10","author":"P Valkovic","year":"2015","unstructured":"Valkovic P, Minar M, Singliarova H et al (2015) Pain in Parkinson\u2019s disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life. PLoS One 10:e0136541. https:\/\/doi.org\/10.1371\/journal.pone.0136541","journal-title":"PLoS One"},{"key":"3142_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00246-y","volume":"7","author":"F Valldeoriola","year":"2021","unstructured":"Valldeoriola F, Catal\u00e1n MJ, Escamilla-Sevilla F et al (2021) Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease. NPJ Parkinsons Dis 7:108. https:\/\/doi.org\/10.1038\/s41531-021-00246-y","journal-title":"NPJ Parkinsons Dis"},{"key":"3142_CR263","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/lary.25481","volume":"126","author":"MRA Van Hooren","year":"2016","unstructured":"Van Hooren MRA, Baijens LWJ, Vos R et al (2016) Voice- and swallow-related quality of life in idiopathic Parkinson\u2019s disease. Laryngoscope 126:408\u2013414. https:\/\/doi.org\/10.1002\/lary.25481","journal-title":"Laryngoscope"},{"key":"3142_CR264","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/imj.13754","volume":"48","author":"N Vijiaratnam","year":"2018","unstructured":"Vijiaratnam N, Hewer S, Varley S et al (2018) Levodopa\u2010carbidopa intestinal gel: is the naso\u2010jejunal phase a redundant convention? Intern Med J 48:469\u2013471. https:\/\/doi.org\/10.1111\/imj.13754","journal-title":"Intern Med J"},{"key":"3142_CR265","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00415-008-0994-4","volume":"255","author":"M Visser","year":"2008","unstructured":"Visser M, Van Rooden SM, Verbaan D et al (2008) A comprehensive model of health-related quality of life in Parkinson\u2019s disease. J Neurol 255:1580\u20131587. https:\/\/doi.org\/10.1007\/s00415-008-0994-4","journal-title":"J Neurol"},{"key":"3142_CR266","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1524-4733.2008.00430.x","volume":"12","author":"M Visser","year":"2009","unstructured":"Visser M, Verbaan D, Van Rooden S et al (2009) A longitudinal evaluation of health-related quality of life of patients with Parkinson\u2019s disease. Value Health 12:392\u2013396. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00430.x","journal-title":"Value Health"},{"key":"3142_CR267","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.22496","volume":"24","author":"J Volkmann","year":"2009","unstructured":"Volkmann J, Albanese A, Kulisevsky J et al (2009) Long\u2010term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson\u2019s disease. Mov Disord 24:1154\u20131161. https:\/\/doi.org\/10.1002\/mds.22496","journal-title":"Mov Disord"},{"key":"3142_CR268","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson diseaseA randomized controlled trial. JAMA 301:63. https:\/\/doi.org\/10.1001\/jama.2008.929","journal-title":"JAMA"},{"key":"3142_CR269","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1212\/WNL.0b013e31825dcdc1","volume":"79","author":"FM Weaver","year":"2012","unstructured":"Weaver FM, Follett KA, Stern M et al (2012) Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 79:55\u201365. https:\/\/doi.org\/10.1212\/WNL.0b013e31825dcdc1","journal-title":"Neurology"},{"key":"3142_CR270","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","volume":"41","author":"Whoqol Group","year":"1995","unstructured":"Whoqol Group (1995) The world health organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41:1403\u20131409. https:\/\/doi.org\/10.1016\/0277-9536(95)00112-K","journal-title":"Soc Sci Med"},{"key":"3142_CR271","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/mds.20347","volume":"20","author":"CL Wielinski","year":"2005","unstructured":"Wielinski CL, Erickson-Davis C, Wichmann R et al (2005) Falls and injuries resulting from falls among patients with Parkinson\u2019s disease and other parkinsonian syndromes. Mov Disord 20:410\u2013415. https:\/\/doi.org\/10.1002\/mds.20347","journal-title":"Mov Disord"},{"key":"3142_CR272","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1474-4422(10)70093-4","volume":"9","author":"A Williams","year":"2010","unstructured":"Williams A, Gill S, Varma T et al (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson\u2019s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9:581\u2013591. https:\/\/doi.org\/10.1016\/S1474-4422(10)70093-4","journal-title":"Lancet Neurol"},{"key":"3142_CR273","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s40120-025-00747-5","volume":"14","author":"N Williamson","year":"2025","unstructured":"Williamson N, Morel T, Bradley H et al (2025) Understanding the patient experience of advanced Parkinson\u2019s disease: qualitative research with patients and expert clinicians to identify symptoms and associated health-related quality of life impacts. Neurol Ther 14:1383\u20131417. https:\/\/doi.org\/10.1007\/s40120-025-00747-5","journal-title":"Neurol Ther"},{"key":"3142_CR274","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00415-009-5389-7","volume":"257","author":"Y Winter","year":"2010","unstructured":"Winter Y, Campenhausen S, Gasser J et al (2010a) Social and clinical determinants of quality of life in Parkinson\u2019s disease in Austria: a cohort study. J Neurol 257:638\u2013645. https:\/\/doi.org\/10.1007\/s00415-009-5389-7","journal-title":"J Neurol"},{"key":"3142_CR275","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.parkreldis.2009.11.012","volume":"16","author":"Y Winter","year":"2010","unstructured":"Winter Y, Von Campenhausen S, Popov G et al (2010b) Social and clinical determinants of quality of life in Parkinson\u2019s disease in a Russian cohort study. Parkinsonism Relat Disord 16:243\u2013248. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.11.012","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR276","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.parkreldis.2011.01.003","volume":"17","author":"Y Winter","year":"2011","unstructured":"Winter Y, Von Campenhausen S, Arend M et al (2011) Health-related quality of life and its determinants in Parkinson\u2019s disease: results of an Italian cohort study. Parkinsonism Relat Disord 17:265\u2013269. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.01.003","journal-title":"Parkinsonism Relat Disord"},{"key":"3142_CR277","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1212\/WNL.59.3.408","volume":"59","author":"T Witjas","year":"2002","unstructured":"Witjas T, Kaphan E, Azulay JP et al (2002) Nonmotor fluctuations in Parkinson\u2019s disease: frequent and disabling. Neurology 59:408\u2013413. https:\/\/doi.org\/10.1212\/WNL.59.3.408","journal-title":"Neurology"},{"key":"3142_CR278","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jns.2011.06.028","volume":"310","author":"K Witt","year":"2011","unstructured":"Witt K, Daniels C, Krack P et al (2011) Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson\u2019s disease. J Neurol Sci 310:261\u2013266. https:\/\/doi.org\/10.1016\/j.jns.2011.06.028","journal-title":"J Neurol Sci"},{"key":"3142_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45110-5","volume":"9","author":"J Wu","year":"2019","unstructured":"Wu J, Lim E-C, Nadkarni NV et al (2019) The impact of levodopa therapy-induced complications on quality of life in Parkinson\u2019s disease patients in Singapore. Sci Rep 9:9248. https:\/\/doi.org\/10.1038\/s41598-019-45110-5","journal-title":"Sci Rep"},{"key":"3142_CR280","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2169\/internalmedicine.52.8617","volume":"52","author":"T Yamanishi","year":"2013","unstructured":"Yamanishi T, Tachibana H, Oguru M et al (2013) Anxiety and depression in patients with Parkinson\u2019s disease. Intern Med 52:539\u2013545. https:\/\/doi.org\/10.2169\/internalmedicine.52.8617","journal-title":"Intern Med"},{"key":"3142_CR281","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000479111","volume":"17","author":"J-E Yoon","year":"2017","unstructured":"Yoon J-E, Kim JS, Jang W et al (2017) Gender differences of nonmotor symptoms affecting quality of life in Parkinson disease. Neurodegener Dis 17:276\u2013280. https:\/\/doi.org\/10.1159\/000479111","journal-title":"Neurodegener Dis"},{"key":"3142_CR282","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3171\/2016.10.JNS16758","volume":"128","author":"M Zaaroor","year":"2018","unstructured":"Zaaroor M, Sinai A, Goldsher D et al (2018) Magnetic resonance\u2013guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson\u2019s disease and essential tremor cases. J Neurosurg 128:202\u2013210. https:\/\/doi.org\/10.3171\/2016.10.JNS16758","journal-title":"J Neurosurg"},{"key":"3142_CR283","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/mds.10698","volume":"19","author":"M \u017bach","year":"2004","unstructured":"\u017bach M, Friedman A, S\u0142awek J, Derejko M (2004) Quality of life in Polish patients with long-lasting Parkinson\u2019s disease. Mov Disord 19:667\u2013672. https:\/\/doi.org\/10.1002\/mds.10698","journal-title":"Mov Disord"},{"key":"3142_CR284","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00415-009-5121-7","volume":"256","author":"LB Zahodne","year":"2009","unstructured":"Zahodne LB, Okun MS, Foote KD et al (2009) Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. J Neurol 256:1321\u20131329. https:\/\/doi.org\/10.1007\/s00415-009-5121-7","journal-title":"J Neurol"},{"key":"3142_CR285","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106450","volume":"201","author":"J Zhang","year":"2021","unstructured":"Zhang J, Li J, Chen F et al (2021) STN versus GPi deep brain stimulation for dyskinesia improvement in advanced Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. Clin Neurol Neurosurg 201:106450. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106450","journal-title":"Clin Neurol Neurosurg"},{"key":"3142_CR286","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cns.13549","volume":"27","author":"N Zhao","year":"2021","unstructured":"Zhao N, Yang Y, Zhang L et al (2021) Quality of life in Parkinson\u2019s disease: a systematic review and meta\u2010analysis of comparative studies. CNS Neurosci Ther 27:270\u2013279. https:\/\/doi.org\/10.1111\/cns.13549","journal-title":"CNS Neurosci Ther"},{"key":"3142_CR287","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s11136-009-9500-4","volume":"18","author":"L \u017diropa\u0111a","year":"2009","unstructured":"\u017diropa\u0111a L, Stefanova E, Potrebi\u0107 A, Kosti\u0107 VS (2009) Quality of life in Serbian patients with Parkinson\u2019s disease. Qual Life Res 18:833\u2013839. https:\/\/doi.org\/10.1007\/s11136-009-9500-4","journal-title":"Qual Life Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03142-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:17:11Z","timestamp":1774955831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03142-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":287,"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03142-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JRA: has received honoraria for lectures from Zambon and Bial. LB: none. JK: Consulting fees: Roche, Zambon; Honoraria: Zambon, Teva, Bial, UCB; Research funding: Roche, Zambon, Ciberned; ISCIII; Fundaci\u00f3 La Marat\u00f3 de TV3. JP: has received honoraria from UCB, Zambon, AbbVie, Italfarmaco, Allergan, Ipsen, Bial and reports grants from Fundaci\u00f3 la Marato de TV3, Fondo de Investigaciones Sanitarias and from Instituto de Salud Carlos III.Declarations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}